<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Mol Sci</journal-id><journal-id journal-id-type="iso-abbrev">Int J Mol Sci</journal-id><journal-id journal-id-type="publisher-id">ijms</journal-id><journal-title-group><journal-title>International Journal of Molecular Sciences</journal-title></journal-title-group><issn pub-type="epub">1422-0067</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6032224</article-id><article-id pub-id-type="doi">10.3390/ijms19061781</article-id><article-id pub-id-type="publisher-id">ijms-19-01781</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Annexins in Translational Research: Hidden Treasures to Be Found </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Schloer</surname><given-names>Sebastian</given-names></name></contrib><contrib contrib-type="author"><name><surname>Pajonczyk</surname><given-names>Denise</given-names></name></contrib><contrib contrib-type="author"><name><surname>Rescher</surname><given-names>Ursula</given-names></name><xref rid="c1-ijms-19-01781" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-ijms-19-01781">Institute of Medical Biochemistry, Centre for Molecular Biology of Inflammation, University of Muenster, Von-Esmarch-Street 56, D-48149 Muenster, Germany; <email>sebastschl@gmx.de</email> (S.S.); <email>Denise.Pajonczyk@ukmuenster.de</email> (D.P.)</aff><author-notes><corresp id="c1-ijms-19-01781"><label>*</label>Correspondence: <email>rescher@uni-muenster.de</email>; Tel.: +49-251-83-52121</corresp></author-notes><pub-date pub-type="epub"><day>15</day><month>6</month><year>2018</year></pub-date><pub-date pub-type="collection"><month>6</month><year>2018</year></pub-date><volume>19</volume><issue>6</issue><elocation-id>1781</elocation-id><history><date date-type="received"><day>25</day><month>5</month><year>2018</year></date><date date-type="accepted"><day>12</day><month>6</month><year>2018</year></date></history><permissions><copyright-statement>© 2018 by the authors.</copyright-statement><copyright-year>2018</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p><SecTag type="ABS"><text><SENT sid="1" pm="."><plain>The vertebrate annexin superfamily (AnxA) consists of 12 members of a calcium (Ca2+) and phospholipid binding protein family which share a high structural homology. </plain></SENT>
<SENT sid="2" pm="."><plain>In keeping with this hallmark feature, annexins have been implicated in the Ca2+-controlled regulation of a broad range of membrane events. </plain></SENT>
<SENT sid="3" pm="."><plain>In this review, we identify and discuss several themes of annexin actions that hold a potential therapeutic value, namely, the regulation of the immune response and the control of tissue homeostasis, and that repeatedly surface in the annexin activity profile. </plain></SENT>
<SENT sid="4" pm="."><plain>Our aim is to identify and discuss those annexin properties which might be exploited from a translational science and specifically, a clinical point of view. </plain></SENT>
</text></SecTag></p></abstract><SecTag type="KEYWORD"><kwd-group><kwd>annexins</kwd><kwd>inflammation</kwd><kwd>host-pathogen interplay</kwd><kwd>drug target</kwd><kwd>translational research</kwd></kwd-group></SecTag></article-meta></front><body><SecTag type="INTRO"><sec id="sec1-ijms-19-01781"><title><text><SENT sid="5" pm="."><plain>1. </plain></SENT>
<SENT sid="6" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="7" pm="."><plain>Annexins stepped into the light in 1978, when a soluble protein was isolated from bovine adrenal glands that caused the aggregation of secretory vesicles in vitro when free Ca2+ was present [1]. </plain></SENT>
<SENT sid="8" pm="."><plain>This protein, initially called “synexin”, turned out to be the first discovered member of a new protein family, the annexins [2]. </plain></SENT>
<SENT sid="9" pm="."><plain>The Ca2+-dependent binding to phospholipid-containing membranes turned out to be their hallmark, mediated by their signature feature, the annexin repeat. </plain></SENT>
<SENT sid="10" pm="."><plain>More than 500 different members of the superfamily have now been identified [3]. </plain></SENT>
<SENT sid="11" pm="."><plain>According to the official nomenclature proposed in 1999, the 12 annexins commonly found in vertebrates constitute the A subclass [4]. </plain></SENT>
<SENT sid="12" pm="."><plain>Structurally, annexins all share the characteristic and highly conserved “core” domain, usually made up of four annexin repeats, each of which typically contains a Ca2+-binding motif and mediates the specific binding to negatively charged phospholipids. </plain></SENT>
<SENT sid="13" pm="."><plain>In 1990, the first crystal structure (of AnxA5) confirmed the predictions [5]. </plain></SENT>
<SENT sid="14" pm="."><plain>The tightly packed and slightly convex annexin core domain is linked to an N-terminal part (sometimes also called the “head” or “tail” domain) that is unique for a given annexin. </plain></SENT>
<SENT sid="15" pm="."><plain>N-terminal tails are surprisingly diverse in length and sequence, and sometimes contain binding sites for interaction partners, including members of the S100 family of EF-hand-containing Ca2+-binding proteins [6]. </plain></SENT>
<SENT sid="16" pm="."><plain>In several annexins, the tail is a substrate for kinases that have a strong influence on a wide variety of signal pathways, such as the proto-oncogene tyrosine-kinase Src and the Ca2+-controlled serine-threonine kinase PKC [7,8,9]. </plain></SENT>
<SENT sid="17" pm="."><plain>Phosphorylation is thought to regulate the protein function [5,10] and has been reported to control secretion, at least in the case of AnxA1 and A2, through a yet unknown unconventional pathway of these otherwise cytosolic proteins [11,12,13,14,15]. </plain></SENT>
<SENT sid="18" pm="."><plain>Not surprisingly, annexins have been implicated in the regulation of a broad range of cellular and physiological processes that are linked to cellular membranes, such as vesicle organization, membrane trafficking and scaffolding, endo- and exocytosis, and membrane/cytoskeleton interactions [16,17,18,19,20,21]. </plain></SENT>
<SENT sid="19" pm="."><plain>Membrane dynamics is also a recurrent theme in host–pathogen interactions, and annexins might function as host cell-derived auxiliary proteins in shaping the microbe–host interplay [22]. </plain></SENT>
<SENT sid="20" pm="."><plain>In recent years, a growing number of annexin knock out (KO) mouse models have been constructed [23], and they will certainly prove to be useful tools for investigating annexin functions, both as drugs and therapeutic targets. </plain></SENT>
</text></p></sec></SecTag><sec id="sec2-ijms-19-01781"><title><text><SENT sid="21" pm="."><plain>2. </plain></SENT>
<SENT sid="22" pm="."><plain>Extracellular Functions—Detection of Phosphatidylserine and Immuno-Evasion </plain></SENT>
</text></title><p><text><SENT sid="23" pm="."><plain>During pathophysiological responses, typical changes in the membrane composition and loss of membrane asymmetry are repeatedly observed. </plain></SENT>
<SENT sid="24" pm="."><plain>A prominent feature is the translocation of phosphatidylserine (PS), which in viable cells is located in the cytosol-facing leaflet of the plasma membrane, to the outside-facing leaflet of the apoptotic cell membrane [24]. </plain></SENT>
<SENT sid="25" pm="."><plain>In the presence of Ca2+, PS is a high-affinity ligand for the annexins and Ca2+-dependent PS binding is in fact, a defining trait of the annexin family [25]. </plain></SENT>
<SENT sid="26" pm="."><plain>For AnxA5, a KD value of 5 × 10−10 in the presence of Ca2+ [26] underscores the high selectivity in its preference for PS over other negatively charged phospholipids, and this specificity is the reason behind the wide use of labelled AnxA5 for the identification of apoptotic cells [27], for example in flow cytometry applications [28,29]. </plain></SENT>
</text></p><p><text><SENT sid="27" pm="."><plain>The surface-exposed PS assists in the recognition and subsequent phagocytic engulfment, of dying cells [30]. </plain></SENT>
<SENT sid="28" pm="."><plain>This process is called efferocytosis and is immune-calming in its nature [30] and seems to depend on the concomitant externalization of AnxA1 [31], which is part of the apoptotic cell-associated molecular patterns (ACAMPs) [32] that is presented by dying cells and conveys the switch towards an anti-inflammatory response. </plain></SENT>
<SENT sid="29" pm="."><plain>In accordance with the function as an “eat-me” signal, which most likely includes the acquisition of PS-bound anxA1 on the outer surface, phagocytosis of PS-decorated red blood cells is inhibited when PS is masked [33], for example through PS-binding proteins. </plain></SENT>
<SENT sid="30" pm="."><plain>Recent findings suggest that exposition of PS on the outer leaflet is not confined to apoptosis but appears to act as an evolutionary conserved global immunosuppressive signal [34], and is also found on the surface of cancer cells [35]. </plain></SENT>
<SENT sid="31" pm="."><plain>Unfortunately, in this context, PS exposure is not linked to cell elimination but seems to function in immune evasion [34], which, like in apoptotic cells, might depend on cell surface associated AnxA1 [36]. </plain></SENT>
<SENT sid="32" pm="."><plain>Blocking of PS with AnxA5 might be a strategy to antagonize the immune-suppression and help establish an anti-tumor immune reaction. </plain></SENT>
<SENT sid="33" pm="."><plain>Furthermore, AnxA5 might be used for the development of selective molecular imaging probes for cancer diagnosis and disease management [29,37] and importantly, for targeting drugs to the cancer cells [25,35]. </plain></SENT>
</text></p></sec><sec id="sec3-ijms-19-01781"><title><text><SENT sid="34" pm="."><plain>3. </plain></SENT>
<SENT sid="35" pm="."><plain>Extracellular Functions—Annexins and Coagulation </plain></SENT>
</text></title><p><text><SENT sid="36" pm="."><plain>Exposure of PS is also an important step in the regulation of blood clotting [38]. </plain></SENT>
<SENT sid="37" pm="."><plain>PS on the surface of endothelial cells or membrane vesicles derived from activated platelets greatly enhances the pro-thrombin/thrombin conversion which is a central unit in coagulation [39]. </plain></SENT>
<SENT sid="38" pm="."><plain>Annexin A5 is abundantly found on the surface of the syncytiotrophoblast, which covers the placental surface, and the AnxA5 layer is considered to protect the placenta from abnormal coagulation [40]. </plain></SENT>
<SENT sid="39" pm="."><plain>Furthermore, a polymorphism in the AnxA5 gene was found to be associated with recurrent pregnancy loss. </plain></SENT>
<SENT sid="40" pm="."><plain>Women with the SNP in the AnxA5 gene had a significantly higher risk of fetal loss than non-carriers [41]. </plain></SENT>
<SENT sid="41" pm="."><plain>The AnxA5 anticoagulant function might depend on its well-established property to self-assemble on PS-containing membranes into an extensive two-dimensional crystal lattice [42] that hinders the assembly of the pro-coagulant complexes. </plain></SENT>
<SENT sid="42" pm="."><plain>In line with such protective function in the blood clotting regulation, anti-AnxA5 autoantibodies are found in patients suffering from anti-phospholipid syndrome [43], a disease that manifests clinically as recurrent thrombotic events and is associated with fetal loss [44]. </plain></SENT>
<SENT sid="43" pm="."><plain>The occurrence of AnxA5 autoantibodies is also linked to autoimmune disorders [45,46] as observed in some patients suffering from multiple sclerosis or systemic lupus erythematosus. </plain></SENT>
<SENT sid="44" pm="."><plain>The current therapeutic strategy is long-term oral anticoagulation. </plain></SENT>
<SENT sid="45" pm="."><plain>Here, AnxA5 could be used to selectively neutralize the pathologic AnxA5 autoantibodies in vivo. </plain></SENT>
</text></p><p><text><SENT sid="46" pm="."><plain>Among the many functions exerted by thrombin is the conversion of fibrinogen to fibrin which, together with platelets, forms a stable haemostatic plug that seals the injured vessel wall. </plain></SENT>
<SENT sid="47" pm="."><plain>To avoid excessive clot formation, the damaged endothelium slowly secrets components that assist in the conversion of plasminogen entrapped in the clot to enzymatically active plasmin, which breaks down the fibrin mesh. </plain></SENT>
<SENT sid="48" pm="."><plain>AnxA2, possibly as a heterotetramer together with its ligand S100A10, was demonstrated to enhance plasmin generation [47,48]. </plain></SENT>
<SENT sid="49" pm="."><plain>Consistently, AnxA2 KO mice present defective fibrinolysis and increased thrombotic vascular occlusion and impaired neovascularization [49]. </plain></SENT>
<SENT sid="50" pm="."><plain>Blast cells of patients with acute promyelocytic leukemia (APL) express AnxA2 to a high amount [50], which might explain the haemorrhagic complications observed in APL patients. </plain></SENT>
<SENT sid="51" pm="."><plain>In line with the impact of AnxA2 on coagulopathy [50], treatment with the retinoic acid receptor ligand, all-trans retinoic acid (ATRA), attenuates AnxA2 expression and improves clinical resolution. </plain></SENT>
<SENT sid="52" pm="."><plain>Thus, annexin-based biologicals might serve as novel agents that open new therapeutic options and might be part of the management of such diseases in the future. </plain></SENT>
</text></p></sec><sec id="sec4-ijms-19-01781"><title><text><SENT sid="53" pm="."><plain>4. </plain></SENT>
<SENT sid="54" pm="."><plain>Extracellular Functions—Annexins as Ligands of Defined Inflammation-Related Receptors </plain></SENT>
</text></title><p><text><SENT sid="55" pm="."><plain>A conceptually straightforward approach is to therapeutically exploit those annexins which function as endogenous ligands for known receptors. </plain></SENT>
<SENT sid="56" pm="."><plain>In this regard, the most prominent annexin is certainly AnxA1. </plain></SENT>
<SENT sid="57" pm="."><plain>Still under its former name lipocortin 1, AnxA1 gained considerable interest as a key mediator of glucocorticoid actions in inflammation. </plain></SENT>
<SENT sid="58" pm="."><plain>AnxA1 deficient mice do not respond to glucocorticoid treatment under inflammatory conditions [51]. </plain></SENT>
<SENT sid="59" pm="."><plain>The full-length protein as well as its famous Ac2-26 N-terminal peptide pharmacophore, which might be proteolytically released from the full length protein [32,52], act in an anti-inflammatory manner in many experimental conditions, and we refer the reader to the many excellent and comprehensive review articles on that topic [53,54,55,56]. </plain></SENT>
<SENT sid="60" pm="."><plain>A molecular explanation was provided by the discovery that both AnxA1 and the Ac2-26 peptide specifically bind and activate the formyl-peptide receptor (FPR) subfamily [57,58] of heptahelical, G-protein coupled cell surface receptors. </plain></SENT>
<SENT sid="61" pm="."><plain>Most of the reported AnxA1 anti-inflammatory functions depend on binding to FPRs. </plain></SENT>
<SENT sid="62" pm="."><plain>However, it is entirely possible that additional signaling mechanisms elicited through yet unknown signalling receptors are involved, as the recognition of an annexin core (which can also be derived from annexins other than A1) also contributes to an immune-modulation [59]. </plain></SENT>
<SENT sid="63" pm="."><plain>In humans, three members of the FPR family are found: FPR1, FPR2, and FPR3, whereas in mice at least eight FPRs are expressed [60]. </plain></SENT>
<SENT sid="64" pm="."><plain>The most prominent receptors among the FPR family expressed in the murine model are FPR1 and FPR2 [61]. </plain></SENT>
<SENT sid="65" pm="."><plain>FPR1 and FPR2 are predominantly expressed on the surface of many immune cells (e.g., neutrophils, macrophages, dendritic cells) but also found in endo- and epithelial cells [62]. </plain></SENT>
<SENT sid="66" pm="."><plain>A broad range of FPR1 ligands, both agonist and antagonists, have been described [63], and autocrine/paracrine signalling of externalized AnxA1 protein and/or its peptides via the FPRs might explain its well-known immune-modulatory and pro-resolving actions. </plain></SENT>
<SENT sid="67" pm="."><plain>Upregulation of AnxA1 expression is observed in several inflammatory conditions [64] and thought to function in resolution and tissue protection [65]. </plain></SENT>
<SENT sid="68" pm="."><plain>Indeed, studies on the use of Ac2-26-containing nanocapsules in the treatment of mucosal injury in the murine model, reported enhanced colonic wound healing, both in the acute and chronic situation [66]. </plain></SENT>
<SENT sid="69" pm="."><plain>Interestingly, a small peptide derived from the AnxA1 N-terminus attenuated experimental colitis in mice [67]. </plain></SENT>
<SENT sid="70" pm="."><plain>Chronic inflammation is also observed in obesity [68]. </plain></SENT>
<SENT sid="71" pm="."><plain>Interestingly, AnxA1 KO mice on a high-fat diet are more prone to obesity than the control animals [69], and FPR2 activation improved systemic insulin sensitivity [70]. </plain></SENT>
</text></p><p><text><SENT sid="72" pm="."><plain>The AnxA1/FPR signaling axis might constitute an attractive target for the treatment of cardiovascular diseases. </plain></SENT>
<SENT sid="73" pm="."><plain>We only give a cursory overview as we want to draw the reader’s attention to the excellent review articles included in this special issue “Annexins—Closing the Gap between Fundamental and Translational Research”. </plain></SENT>
<SENT sid="74" pm="."><plain>A lowered AnxA1 expression in plaques obtained from patients with carotid stenosis correlates with neurological symptoms [71]. </plain></SENT>
<SENT sid="75" pm="."><plain>Correspondingly, vulnerable plaque regions obtained from human carotid endarterectomy were shown to have less pro-resolving factors, such as resolvin D1 (RvD1), compared to more stable regions [72]. </plain></SENT>
<SENT sid="76" pm="."><plain>RvD1 is another ligand for FPR2 [73], thus indicating a potential therapeutic use of AnxA1 to support the resolution phase, suppress plaque progression, and enhance plaque stability. </plain></SENT>
<SENT sid="77" pm="."><plain>A growing body of evidence also points at an anti-inflammatory and neuroprotective function of AnxA1 in the brain, and AnxA1-derived molecules might emerge as promising tools in the treatment of brain diseases, including stroke and neurodegenerative disorders [74,75]. </plain></SENT>
<SENT sid="78" pm="."><plain>The decisive role of AnxA1 in stroke development and progression has been highlighted in a global murine stroke model mimicking cerebral ischemia caused by atherosclerosis, which is accompanied by cardiac arrest. </plain></SENT>
<SENT sid="79" pm="."><plain>Ischemic mice treated with AnxA1or the Ac2-26 peptide presented reduced infarct size, less cerebral edema, and improved neurological score [76]. </plain></SENT>
<SENT sid="80" pm="."><plain>Furthermore, Ac2-26 prevents neutrophil-platelet aggregate formation within cerebral microvessels through the interaction with FPR2 [77]. </plain></SENT>
</text></p><p><text><SENT sid="81" pm="."><plain>A caveat to the generalized use of AnxA1 for treatment of excess inflammatory conditions is the observation that LPS, a highly potent pro-inflammatory component derived from the bacterial wall of gram-negative bacteria, triggers the upregulation of AnxA1 expression in a variety of cell types e.g., neutrophils [78]. </plain></SENT>
<SENT sid="82" pm="."><plain>Indeed, elevated AnxA1 plasma levels are found in 56% of septic patients after hospital admission [79]. </plain></SENT>
<SENT sid="83" pm="."><plain>While initially beneficial [78], it remains to be investigated whether excess LPS-induced AnxA1 externalization might cause the so-called endotoxin resistance, a dangerous refractive state of the innate immune system characterized by a lowered response towards a second exposure to bacterial lipopolysaccharide [80]. </plain></SENT>
<SENT sid="84" pm="."><plain>However, the target delivery of AnxA1-derived compounds has tremendous promise to treat a range of inflammatory conditions. </plain></SENT>
</text></p><p><text><SENT sid="85" pm="."><plain>AnxA2 not only impacts fibrinolysis but (in its heterotetrameric form together with S100A10) affects the Toll-like receptor (TLR) signaling. </plain></SENT>
<SENT sid="86" pm="."><plain>The AnxA2-S100A10 complex activates human and murine macrophages through the TLR4-MyD88 pathway, although the cell’s responsiveness requires an additional and yet unknown factor [81,82,83]. </plain></SENT>
<SENT sid="87" pm="."><plain>Signaling through the TRAM/TRIF-module of the TLR4 pathway was reported to attenuate Klebsiella-induced lung inflammation in a murine model of acute pneumonia [83]. </plain></SENT>
<SENT sid="88" pm="."><plain>Monomeric AnxA2 was also shown to bind to and activate TLR2 via its N-terminal domain, thus assisting in the differentiation of antigen-presenting cells [84]. </plain></SENT>
<SENT sid="89" pm="."><plain>Extracellular AnxA2 was shown to also interact with the proprotein convertase subtilisin/kexin-type 9 (PCSK9), thus interfering with PCSK9-mediated degradation of the hepatic low-density lipoprotein receptor (LDLR) [85,86,87]. </plain></SENT>
<SENT sid="90" pm="."><plain>Because PCSK9 reduces the number of LDL receptors on the liver cell membrane, PCSK9 inhibitors can be used to increase the number of cell surface LDL receptors and thereby reduce cholesterol levels in the blood. </plain></SENT>
<SENT sid="91" pm="."><plain>Here, AnxA2 might be used as a PCSK9 inhibitor to treat hypercholesterolaemia. </plain></SENT>
</text></p><p><text><SENT sid="92" pm="."><plain>In search of the molecular mechanism underlying the stimulatory effects of AnxA2 on human osteoclast formation [88,89], a novel type I membrane protein was identified as a putative AnxA2 receptor [90]. </plain></SENT>
<SENT sid="93" pm="."><plain>A recent study linked a single nucleotide polymorphism (SNP) in the AnxA2 gene (rs7170178) to osteonecrosis in sickle cell patients. </plain></SENT>
<SENT sid="94" pm="."><plain>The SNP frequency of the AnxA2 gene polymorphism was higher in sickle cell osteonecrosis patients than those without osteonecrosis [91]. </plain></SENT>
<SENT sid="95" pm="."><plain>Interaction of AnxA2 with the AnxA2 receptor also mediates adhesion and activation of the cells responsible for the initiation and maintenance of multiple myeloma [92] and this signal pathway could be used as a therapeutic target. </plain></SENT>
</text></p></sec><sec id="sec5-ijms-19-01781"><title><text><SENT sid="96" pm="."><plain>5. </plain></SENT>
<SENT sid="97" pm="."><plain>Intracellular Functions in Pathophysiological Scenarios </plain></SENT>
</text></title><p><text><SENT sid="98" pm="."><plain>The following sections will cover those intracellular functions of annexins which are of potential relevance in pathophysiological scenarios. </plain></SENT>
<SENT sid="99" pm="."><plain>In the simplest approach, characteristic changes in the annexin expression profile might be used to diagnose and monitor diseases and to predict and evaluate therapeutic success. </plain></SENT>
<SENT sid="100" pm="."><plain>It is entirely possible that the relative expression levels of several annexins constitute valuable panels of biomarkers, and that such an annexin-based multibiomarker-model could be used to estimate the disease risk. </plain></SENT>
<SENT sid="101" pm="."><plain>Approaches addressing intracellular proteins are challenging and require sophisticated technologies that are only beginning to emerge. </plain></SENT>
<SENT sid="102" pm="."><plain>In this case, annexins might be used for gene and cell therapy approaches or might serve as druggable targets for cell-penetrating small molecules that interfere with or mimic annexin functions. </plain></SENT>
<SENT sid="103" pm="."><plain>Additionally, the intracellular delivery of annexin-derived therapeutics (e.g., as cell-penetrating fusion peptides) might be exploited in intracellular protein therapy. </plain></SENT>
</text></p><sec id="sec5dot1-ijms-19-01781"><title><text><SENT sid="104" pm="."><plain>5.1. </plain></SENT>
<SENT sid="105" pm="."><plain>Intracellular functions—Annexins as Biomarkers </plain></SENT>
</text></title><p><text><SENT sid="106" pm="."><plain>Changes in cellular or tissue expression levels have been reported for several annexins and a broad range of diseases (Figure 1), suggesting a potential use to determine onset and progression of disease and to monitor therapeutic success. </plain></SENT>
<SENT sid="107" pm="."><plain>The following studies are exemplary only and illustrate the potential use of determining annexin expression profiles for the early detection of common cancers. </plain></SENT>
</text></p><p><text><SENT sid="108" pm="."><plain>Massive dysregulation of annexin expression patterns occur during tumorigenesis. </plain></SENT>
<SENT sid="109" pm="."><plain>For instance, serum levels of AnxA1 are significantly elevated in lung cancer patients. </plain></SENT>
<SENT sid="110" pm="."><plain>Due to the strong association of AnxA1 to the pathological grade and clinical stage, it is a convenient marker for monitoring the course of disease [100]. </plain></SENT>
<SENT sid="111" pm="."><plain>Furthermore, AnxA1 expression is upregulated in skeletal muscle of non-myopathic patients undergoing statin therapy, and was proposed to serve as a biomarker for T-tubular repair in those patients [101]. </plain></SENT>
</text></p><p><text><SENT sid="112" pm="."><plain>Annexin expression profiles are often changed in tumorous tissues. </plain></SENT>
<SENT sid="113" pm="."><plain>For instance, the AnxA2 expression is significantly associated with tumor size, lymph node metastasis, distant metastasis and clinical stage of laryngeal cancer, and therefore it is a promising candidate for estimating the prognosis of patients with laryngeal carcinoma or gliomas [102]. </plain></SENT>
<SENT sid="114" pm="."><plain>AnxA10 is already used as a biomarker for hepatocellular carcinoma (HCC) and is markedly downregulated during cancer progression [103]. </plain></SENT>
<SENT sid="115" pm="."><plain>The AnxA10 downregulation, together with a characteristic p53 mutation, acts synergistically toward high-grade, high-stage HCC and goes along with poorer prognosis [103]. </plain></SENT>
<SENT sid="116" pm="."><plain>AnxA10 might be useful to identify adenocarcinomas of unknown primary origin, as AnxA10 expression is commonly found in carcinoma of the upper gastrointestinal tract and the pancreatobiliary system [104]. </plain></SENT>
</text></p></sec><sec id="sec5dot2-ijms-19-01781"><title><text><SENT sid="117" pm="."><plain>5.2. </plain></SENT>
<SENT sid="118" pm="."><plain>Intracellular Functions—Regulation of Cytosolic Phospholipase A2 (cPLA2) Enzymatic Activity </plain></SENT>
</text></title><p><text><SENT sid="119" pm="."><plain>Very early on, the ability of annexins, and especially AnxA1 and AnxA2, to inhibit cPLA2, thus interfering with arachidonic acid release and eicosanoid formation, has been acknowledged. </plain></SENT>
<SENT sid="120" pm="."><plain>Mechanistically, the function was explained by competition for the lipid substrates [105,106,107]. </plain></SENT>
<SENT sid="121" pm="."><plain>However, cPLA2 might be inhibited in a more direct manner [108]. </plain></SENT>
<SENT sid="122" pm="."><plain>Given the fundamental role of this enzymatic activity in eicosanoid production, annexins might serve as a starting point to discover new lead structures for further cPLA2 inhibitors. </plain></SENT>
</text></p></sec><sec id="sec5dot3-ijms-19-01781"><title><text><SENT sid="123" pm="."><plain>5.3. </plain></SENT>
<SENT sid="124" pm="."><plain>Intracellular Functions—Cell Surface Presentation of Integral Plasma Membrane Molecules </plain></SENT>
</text></title><p><text><SENT sid="125" pm="."><plain>The AnxA2-S100A10 tetramer has been shown to interact with (and possibly regulate) a number of integral plasma membrane molecules including ion channels and receptors, like the Ca2+-selective Transient Receptor Potential vanilloid type 5 and 6 channels (TRPV5 and TRPV6) [109], the acid-sensing ion channel ASIC [110], the two-pore-domain potassium channel TASK-1 [111], the chloride channel Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) [112] the GPCR CCR10 [113] and the 5-HT1B receptor [114]. </plain></SENT>
<SENT sid="126" pm="."><plain>Interfering with these S100A10 interactions could be envisioned for the treatment of the corresponding diseases, including depression [114], although a beneficial effect of an upregulation of S100A10 expression, e.g., through 1,25-dihydroxyvitamin D3 [109], still needs to be demonstrated. </plain></SENT>
</text></p><p><text><SENT sid="127" pm="."><plain>In many cases, altered annexin expression correlates with changes in migratory behaviour and invasiveness [115,116,117,118,119,120], and an altered cell surface environment might be the underlying cause. </plain></SENT>
<SENT sid="128" pm="."><plain>For instance, regulatory functions in the presentation of cell adhesion proteins, such as integrins, have been elegantly demonstrated for AnxA6 and AnxA8 [115,116]. </plain></SENT>
<SENT sid="129" pm="."><plain>Because these cell surface receptors cluster at focal contacts to form effective cell-cell or cell-matrix contacts, the number of integrins at the cell surface is a critical determinant of a cell’s motility. </plain></SENT>
<SENT sid="130" pm="."><plain>Cell adhesion and movement, in turn, is fundamental to cancer cell metastasis, wound healing, and angiogenesis. </plain></SENT>
<SENT sid="131" pm="."><plain>In this context, the pattern of annexin gene expression may correlate to physiological and pathophysiological wound healing phenotypes. </plain></SENT>
<SENT sid="132" pm="."><plain>Such information would assist in assessing the course of healing within a wound, and in identifying target pathways for appropriate treatment regimes. </plain></SENT>
</text></p></sec><sec id="sec5dot4-ijms-19-01781"><title><text><SENT sid="133" pm="."><plain>5.4. </plain></SENT>
<SENT sid="134" pm="."><plain>Intracellular Functions—Plasma Membrane Repair </plain></SENT>
</text></title><p><text><SENT sid="135" pm="."><plain>Very recently, another important annexin function related to cellular processes controlling damage appeared. </plain></SENT>
<SENT sid="136" pm="."><plain>To maintain a functional plasma membrane (PM), eukaryotic cells are able to repair PM injuries. </plain></SENT>
<SENT sid="137" pm="."><plain>The resealing is Ca2+-dependent and depends on a complex machinery. </plain></SENT>
<SENT sid="138" pm="."><plain>It can probably occur through different mechanisms, depending on the kind and extent of injury. </plain></SENT>
<SENT sid="139" pm="."><plain>PM repair is essential for skeletal muscle homeostasis, and defective PM repair manifests very impressively in skeletal muscle damage and is linked to degenerative muscle diseases such as myopathies and muscular dystrophies [121]. </plain></SENT>
<SENT sid="140" pm="."><plain>A growing body of research suggests that several annexin family members facilitate the required membrane fusion events during the healing of PM lesions [122,123,124,125,126,127,128]. </plain></SENT>
<SENT sid="141" pm="."><plain>Here, gene therapy, i.e., the transfer of DNA encoding functional annexin proteins into the target cells, might be used to treat conditions caused by defective PM repair mechanisms. </plain></SENT>
</text></p></sec></sec><sec id="sec6-ijms-19-01781"><title><text><SENT sid="142" pm="."><plain>6. </plain></SENT>
<SENT sid="143" pm="."><plain>Annexins and the Host/Pathogen Interface </plain></SENT>
</text></title><p><text><SENT sid="144" pm="."><plain>The growing appearance of antibiotic resistance is one of the major threats to human health. </plain></SENT>
<SENT sid="145" pm="."><plain>To overcome the emergence of drug-resistant viruses, bacteria, and fungi, therapeutic strategies that aim at targeting host cell factors rather than the pathogen itself are currently being pursued [129]. </plain></SENT>
<SENT sid="146" pm="."><plain>However, most of these novel approaches are still in the very early phases of clinical trials. </plain></SENT>
<SENT sid="147" pm="."><plain>For the development of such novel approaches, detailed knowledge of the manifold host/pathogen interactions that take place during the course of infection, is paramount. </plain></SENT>
<SENT sid="148" pm="."><plain>An obvious target for interventions is the host innate immune response. </plain></SENT>
<SENT sid="149" pm="."><plain>It acts as a first line of defense against pathogen attack, and, not surprisingly, pathogens have evolved sophisticated strategies to overcome these cellular defense mechanisms or even use them to their advantage. </plain></SENT>
<SENT sid="150" pm="."><plain>Trypanosoma cruzi, for example, presents PS on the cell surface of trypomastigote stage in order to mimic the anti-inflammatory effects of apoptotic cells, thus evading the host innate immune response [130]. </plain></SENT>
<SENT sid="151" pm="."><plain>A similar mechanism of apoptotic mimicry to balance inflammation is also used by Toxoplasma gondii [131] and Leishmania braziliensis [132], although it remains to be studied whether the immunomodulatory function also depends on the recruitment of AnxA1. </plain></SENT>
<SENT sid="152" pm="."><plain>However, blocking of the surface-exposed PS by AnxA5 impacts infectivity of Toxoplasma [131] and Leishmania [132]. </plain></SENT>
<SENT sid="153" pm="."><plain>These exemplary observations underscore that the elucidation of a functional role for the annexins during microbial infection, an emerging and rapidly growing field within the annexin research, holds potential for developing annexin-based therapeutic options. </plain></SENT>
</text></p><p><text><SENT sid="154" pm="."><plain>Several annexins are incorporated into virus particles, for example, influenza A virus (IAV) particles contain annexins A1, A2, A4, A5, and A11 [133]. </plain></SENT>
<SENT sid="155" pm="."><plain>In addition to IAV, AnxA1 is found associated with several other viruses [133,134,135,136,137,138,139,140,141]. </plain></SENT>
<SENT sid="156" pm="."><plain>Interestingly, no indications so far suggest that the viruses rely on its immune-modulating capacity to facilitate virus entry, although the AnxA1 receptor FPR2 is involved in IAV replication. </plain></SENT>
<SENT sid="157" pm="."><plain>Notably, FPR2 activation increases viral replication, and FPR2 antagonists protect mice from lethal IAV infections [142,143]. </plain></SENT>
<SENT sid="158" pm="."><plain>A clearer active role during viral infection is found for AnxA2 and AnxA5. </plain></SENT>
<SENT sid="159" pm="."><plain>An exploitation of virus-incorporated AnxA2 to promote the conversion of plasminogen to plasmin on the cell surface was reported to be utilized, at least in a supportive manner, by herpesvirus and IAV [144,145,146,147]. </plain></SENT>
<SENT sid="160" pm="."><plain>Virus-incorporated AnxA5 assists IAV infection through the inhibition of interferon-mediated host cell protection [148]. </plain></SENT>
<SENT sid="161" pm="."><plain>Whether the specific binding of anxA5 to a hepatitis B virus (HBV) surface antigen [149,150] mediates a similar function, thereby affecting the host cell susceptibility to HBV [151,152,153,154] remains to be investigated. </plain></SENT>
<SENT sid="162" pm="."><plain>Although the potential importance of the remaining IAV-associated annexins is still unknown, the above indications point to a function, at least for several annexins, as host-derived virulence factors. </plain></SENT>
<SENT sid="163" pm="."><plain>Furthermore, the most common high-risk human papillomavirus HPV16, which causes benign and malignant mucosal and cutaneous epithelial tumors, induces and utilizes the AnxA2/S100A10 heterotetramer on the host cell surface for effective internalization. </plain></SENT>
<SENT sid="164" pm="."><plain>The complex most likely interacts with the HPV minor capsid protein L2 [155,156]. </plain></SENT>
<SENT sid="165" pm="."><plain>Importantly, interfering with AnxA2/S100A10 complex through the use of small molecule inhibitors markedly impairs HPV16 infection in a cell culture model [157]. </plain></SENT>
<SENT sid="166" pm="."><plain>Because a similar function for AnxA2 as a host cell receptor was also reported for several other viruses, including human cytomegalovirus, enterovirus type 71, rabbit vesivirus, and respiratory syncytial virus [158,159,160,161,162,163], as well as for Pseudomonas aeruginosa and Mycoplasma [164,165,166], such small molecule inhibitors might be of therapeutic value in a broad range of viral and bacterial infections. </plain></SENT>
<SENT sid="167" pm="."><plain>Further host-directed drug therapies might include targeting of other annexin/pathogen interactions, for instance through the use of synthetic mimetic peptides that effectively compete for interaction sites. </plain></SENT>
</text></p><p><text><SENT sid="168" pm="."><plain>Because of their biochemical signature, i.e., the ability to dynamically bind to membrane phospholipids (and for some annexins, to F-actin) in response to fluctuating intracellular Ca2+ concentrations, annexins are perfectly suited to transduce and integrate membrane-related events and signaling. </plain></SENT>
<SENT sid="169" pm="."><plain>While there is a vast body of literature on their participation in e.g., endo- and exocytosis, membrane rearrangement events and cytoskeletal organization, growing evidence suggests that the establishment and control of membranes under non-equilibrium conditions is where the full annexin potential is unlocked. </plain></SENT>
<SENT sid="170" pm="."><plain>A predominant function of these proteins in the assembly of transient membrane domains and the maintenance of membrane integrity under potentially harmful conditions, such as PM disruption (see above) is also in accordance with the fact that annexin KO mice are viable, develop normally and have no evident phenotypic alterations during their lifetime [23]. </plain></SENT>
</text></p><p><text><SENT sid="171" pm="."><plain>Because microbes in the human body intimately associate with the membrane system of their host cells, they have evolved sophisticated strategies to hijack the cell machinery and use it to their advantage [167]. </plain></SENT>
<SENT sid="172" pm="."><plain>For instance, many invading pathogens need to penetrate the PM or endosomal membranes to get access to the cell interior in order to proliferate. </plain></SENT>
<SENT sid="173" pm="."><plain>These pathogen-induced membrane manipulations are potentially harmful, and a clear example is the insertion of pore-forming toxins, such as streptolysin-O (SLO), the pore-forming toxin of Streptococcus pyogenes. </plain></SENT>
<SENT sid="174" pm="."><plain>The host cell perceives the concomitant rise in intracellular Ca2+ as a danger signal indicating PM injury, a situation that closely resembles PM damage induced by mechanical forces. </plain></SENT>
<SENT sid="175" pm="."><plain>In line with their proposed function as part of the repair machinery that kicks in when a high Ca2+ influx is sensed [20,122], several annexins are involved in repairing the PM lesions caused by SLO [168,169]. </plain></SENT>
<SENT sid="176" pm="."><plain>This annexin-mediated resealing, blebbing, and subsequent shedding of the affected PM domains as pore-containing microvesicles is cell-protective and thus might constitute a vital part of the host cell innate immune response. </plain></SENT>
<SENT sid="177" pm="."><plain>The importance of the rapid and effective toxin removal for the host protection has been impressively demonstrated in vivo, as the administration of artificial liposomes that effectively compete with the host cell membranes sequester such toxins and successfully prevent the development of severe sepsis in a murine staphylococcal sepsis model [170]. </plain></SENT>
<SENT sid="178" pm="."><plain>Another example of a pathogen exploiting the host cell PM repair mechanism is the induction of lysosomal exocytosis during the host cell entry process of adenoviruses [171]. </plain></SENT>
<SENT sid="179" pm="."><plain>Fusion of lysosomes with the PM is also a means to control the propagation of intracellular bacteria [172]. </plain></SENT>
<SENT sid="180" pm="."><plain>As annexins are involved in at least certain lysosomal fusion events [173,174], it is highly likely that they also play an important part in these pathogen-related events. </plain></SENT>
</text></p><p><text><SENT sid="181" pm="."><plain>In many cases, annexin-mediated reorganization of intracellular membranes affects the pathogen propagation. </plain></SENT>
<SENT sid="182" pm="."><plain>IAV infection, for instance, is significantly reduced when AnxA6 is overexpressed, causing imbalanced cholesterol levels in the PM and endosomal membranes [175]. </plain></SENT>
<SENT sid="183" pm="."><plain>AnxA2 and A3 are involved in the production of Hepatitis C virus (HCV) particles, presumably through supporting the establishment of the “membranous web”, the highly specialized and supposedly endoplasmatic reticulum (ER)-derived sites of HCV replication in infected cells [176,177,178] and affecting HCV maturation and egress [179]. </plain></SENT>
</text></p><p><text><SENT sid="184" pm="."><plain>These examples are certainly far from being complete, but were selected to highlight the potential therapeutic value of the annexins in the development of novel, host-centered approaches, either as lead substances for drug design or promising targets in pathogen–host cell interactions. </plain></SENT>
</text></p></sec><SecTag type="CONCL"><sec id="sec7-ijms-19-01781"><title><text><SENT sid="185" pm="."><plain>7. </plain></SENT>
<SENT sid="186" pm="."><plain>Conclusions </plain></SENT>
</text></title><p><text><SENT sid="187" pm="."><plain>This review summarizes the potential clinical use of the annexins. </plain></SENT>
<SENT sid="188" pm="."><plain>While by no means exhaustive (we apologize to any colleague whose excellent work had to be excluded in the interest of space), we believe that the special issue “Annexins—Closing the Gap between Fundamental and Translational Research” is a collection of exemplary articles that helps bring together annexin-themed basic science and translational research which will inspire a fresh look and open up a whole new world where these proteins can be conquered. </plain></SENT>
</text></p></sec></SecTag></body><back><SecTag type="ACK_FUND"><ack><title>Acknowledgments</title><p><text4fund><text><SENT sid="189" pm="."><plain>We thank Volker Gerke for his critical and careful reading of the manuscript and his helpful suggestions. </plain></SENT>
</text></text4fund></p></ack></SecTag><notes><title>Author Contributions</title><p>All authors have made substantial contributions to the manuscript. Conceptualization, S.S. and U.R. Data Curation, S.S. and D.P.; Writing—Original Draft Preparation, S.S.; D.P. Writing—Review &amp; Editing, S.S.; D.P.; U.R. Supervision, U.R.; Project Administration, U.R.; Funding Acquisition, U.R.</p></notes><notes><title>Funding</title><p>This work was supported by funding to U.R. from the Interdisciplinary Center of Clinical Research of the Münster Medical School (IZKF, RE2/026/15) and the German Research Foundation (DFG; SFB1009/A06 and SFB 1348/A11). Authors are members of the phi Club of the Münster Alliance for Infection Research.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest. The founding sponsors had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in the decision to publish the results.</p></notes><SecTag type="REF"><ref-list><title>References</title><ref id="B1-ijms-19-01781"><text><SENT sid="190" pm="."><plain>1.CreutzC.E.PazolesC.J.PollardH.B.Identification and purification of an adrenal medullary protein (synexin) that causes calcium-dependent aggregation of isolated chromaffin granulesJ. </plain></SENT>
<SENT sid="191" pm="."><plain>Biol. </plain></SENT>
<SENT sid="192" pm="."><plain>Chem.197825328582866<?supplied-pmid 632306?>632306 </plain></SENT>
</text></ref><ref id="B2-ijms-19-01781"><text><SENT sid="193" pm="."><plain>2.GeisowM.J.WalkerJ.H.BousteadC.TaylorW.Annexins—New family of Ca2+-regulated-phospholipid binding proteinBiosci. </plain></SENT>
<SENT sid="194" pm="."><plain>Rep.1987728929810.1007/BF01121450<?supplied-pmid 2960386?>2960386 </plain></SENT>
</text></ref><ref id="B3-ijms-19-01781"><text><SENT sid="195" pm="."><plain>3.MorganR.FernandezM.P.Structure, Function and Evolution of the Annexin Gene SuperfamilyAnnexins: Biological Importance and Annexin-Related PathologiesBandorowicz-PikulaJ.Kluwer Academic/Plenum PublishersGeorgetown, WA, USA20032137 </plain></SENT>
</text></ref><ref id="B4-ijms-19-01781"><text><SENT sid="196" pm="."><plain>4.MorganR.O.BellD.W.TestaJ.R.FernandezM.P.Human annexin 31 genetic mapping and originGene1999227333810.1016/S0378-1119(98)00597-69931420 </plain></SENT>
</text></ref><ref id="B5-ijms-19-01781"><text><SENT sid="197" pm="."><plain>5.BartonG.J.NewmanR.H.FreemontP.S.CrumptonM.J.Amino acid sequence analysis of the annexin super-gene family of proteinsEur. </plain></SENT>
<SENT sid="198" pm="."><plain>J. </plain></SENT>
<SENT sid="199" pm="."><plain>Biochem.199119874976010.1111/j.1432-1033.1991.tb16076.x<?supplied-pmid 1646719?>1646719 </plain></SENT>
</text></ref><ref id="B6-ijms-19-01781"><text><SENT sid="200" pm="."><plain>6.RescherU.GerkeV.S100A10/p11: Family, friends and functionsPflügers Arch. </plain></SENT>
<SENT sid="201" pm="."><plain>Eur. </plain></SENT>
<SENT sid="202" pm="."><plain>J. </plain></SENT>
<SENT sid="203" pm="."><plain>Physiol.200745557558210.1007/s00424-007-0313-4<?supplied-pmid 17638009?>17638009 </plain></SENT>
</text></ref><ref id="B7-ijms-19-01781"><text><SENT sid="204" pm="."><plain>7.KheifetsV.BrightR.InagakiK.SchechtmanD.Mochly-RosenD.Protein kinase C δ (δPKC)-annexin V interaction: A required step in δPKC translocation and functionJ. </plain></SENT>
<SENT sid="205" pm="."><plain>Biol. </plain></SENT>
<SENT sid="206" pm="."><plain>Chem.2006281232182322610.1074/jbc.M602075200<?supplied-pmid 16785226?>16785226 </plain></SENT>
</text></ref><ref id="B8-ijms-19-01781"><text><SENT sid="207" pm="."><plain>8.EriksonE.EriksonR.L.Identification of a Cellular Protein Substrate Phosphorylated by the Avian Sarcoma Virus- Transforming Gene ProductCell. </plain></SENT>
<SENT sid="208" pm="."><plain>Copyr.19802182983610.1016/0092-8674(80)90446-8 </plain></SENT>
</text></ref><ref id="B9-ijms-19-01781"><text><SENT sid="209" pm="."><plain>9.HayesM.J.MossS.E.Annexin 2 has a dual role as regulator and effector of v-Src in cell transformationJ. </plain></SENT>
<SENT sid="210" pm="."><plain>Biol. </plain></SENT>
<SENT sid="211" pm="."><plain>Chem.2009284102021021010.1074/jbc.M807043200<?supplied-pmid 19193640?>19193640 </plain></SENT>
</text></ref><ref id="B10-ijms-19-01781"><text><SENT sid="212" pm="."><plain>10.GerkeV.MossS.E.Annexins: From Structure to FunctionPhysiol. </plain></SENT>
<SENT sid="213" pm="."><plain>Rev.20028233137110.1152/physrev.00030.2001<?supplied-pmid 11917092?>11917092 </plain></SENT>
</text></ref><ref id="B11-ijms-19-01781"><text><SENT sid="214" pm="."><plain>11.CroxtallJ.D.ChoudhuryQ.FlowerR.J.Glucocorticoids act within minutes to inhibit recruitment of signalling factors to activated EGF receptors through a receptor-dependent, transcription-independent mechanismBr. </plain></SENT>
<SENT sid="215" pm="."><plain>J. </plain></SENT>
<SENT sid="216" pm="."><plain>Pharmacol.200013028929810.1038/sj.bjp.0703272<?supplied-pmid 10807665?>10807665 </plain></SENT>
</text></ref><ref id="B12-ijms-19-01781"><text><SENT sid="217" pm="."><plain>12.JohnC.D.ChristianH.C.MorrisJ.F.FlowerR.J.SolitoE.BuckinghamJ.C.Kinase-dependent regulation of the secretion of thyrotrophin and luteinizing hormone by glucocorticoids and annexin 1 peptidesJ. </plain></SENT>
<SENT sid="218" pm="."><plain>Neuroendocrinol.20031594695710.1046/j.1365-2826.2003.01081.x<?supplied-pmid 12969239?>12969239 </plain></SENT>
</text></ref><ref id="B13-ijms-19-01781"><text><SENT sid="219" pm="."><plain>13.D’AcquistoF.PerrettiM.FlowerR.J.Annexin-A1: A pivotal regulator of the innate and adaptive immune systemsBr. </plain></SENT>
<SENT sid="220" pm="."><plain>J. </plain></SENT>
<SENT sid="221" pm="."><plain>Pharmacol.200815515216910.1038/bjp.2008.252<?supplied-pmid 18641677?>18641677 </plain></SENT>
</text></ref><ref id="B14-ijms-19-01781"><text><SENT sid="222" pm="."><plain>14.SolitoE.ChristianH.C.FestaM.MullaA.TierneyT.FlowerR.J.BuckinghamJ.C.Post-translational modification plays an essential role in the translocation of annexin A1 from the cytoplasm to the cell surfaceFASEB J.2006201498150010.1096/fj.05-5319fje<?supplied-pmid 16720734?>16720734 </plain></SENT>
</text></ref><ref id="B15-ijms-19-01781"><text><SENT sid="223" pm="."><plain>15.HeK.SuiG.XiongH.BroekmanM.J.HuangB.MarcusA.J.HajjarK.A.Feedback regulation of endothelial cell surface plasmin generation by PKC-dependent phosphorylation of annexin A2J. </plain></SENT>
<SENT sid="224" pm="."><plain>Biol. </plain></SENT>
<SENT sid="225" pm="."><plain>Chem.2011286154281543910.1074/jbc.M110.185058<?supplied-pmid 21115493?>21115493 </plain></SENT>
</text></ref><ref id="B16-ijms-19-01781"><text><SENT sid="226" pm="."><plain>16.RescherU.Annexins—Unique membrane binding proteins with diverse functionsJ. </plain></SENT>
<SENT sid="227" pm="."><plain>Cell Sci.20041172631263910.1242/jcs.01245<?supplied-pmid 15169834?>15169834 </plain></SENT>
</text></ref><ref id="B17-ijms-19-01781"><text><SENT sid="228" pm="."><plain>17.HayesM.J.RescherU.GerkeV.MossS.E.Annexin-Actin interactionsTraffic2004557157610.1111/j.1600-0854.2004.00210.x<?supplied-pmid 15260827?>15260827 </plain></SENT>
</text></ref><ref id="B18-ijms-19-01781"><text><SENT sid="229" pm="."><plain>18.CreutzC.E.The annexins and exocytosisScience199225892493110.1126/science.1439804<?supplied-pmid 1439804?>1439804 </plain></SENT>
</text></ref><ref id="B19-ijms-19-01781"><text><SENT sid="230" pm="."><plain>19.MeersP.MealyT.PavlotskyN.TauberA.I.Annexin I-Mediated Vesicular Aggregation: Mechanism and Role in Human NeutrophilsBiochemistry1992316372638210.1021/bi00143a003<?supplied-pmid 1385975?>1385975 </plain></SENT>
</text></ref><ref id="B20-ijms-19-01781"><text><SENT sid="231" pm="."><plain>20.DraegerA.WrayS.BabiychukE.B.Domain architecture of the smooth-muscle plasma membrane: Regulation by annexinsBiochem. </plain></SENT>
<SENT sid="232" pm="."><plain>J.200538730931410.1042/BJ20041363<?supplied-pmid 15537390?>15537390 </plain></SENT>
</text></ref><ref id="B21-ijms-19-01781"><text><SENT sid="233" pm="."><plain>21.McNeilA.K.RescherU.GerkeV.McNeilP.L.Requirement for annexin A1 in plasma membrane repairJ. </plain></SENT>
<SENT sid="234" pm="."><plain>Biol. </plain></SENT>
<SENT sid="235" pm="."><plain>Chem.2006281352023520710.1074/jbc.M606406200<?supplied-pmid 16984915?>16984915 </plain></SENT>
</text></ref><ref id="B22-ijms-19-01781"><text><SENT sid="236" pm="."><plain>22.KuehnlA.MusiolA.RaabeC.A.RescherU.Emerging functions as host cell factors—An encyclopedia of annexin-pathogen interactionsBiol. </plain></SENT>
<SENT sid="237" pm="."><plain>Chem.201639794995910.1515/hsz-2016-0183<?supplied-pmid 27366904?>27366904 </plain></SENT>
</text></ref><ref id="B23-ijms-19-01781"><text><SENT sid="238" pm="."><plain>23.GrewalT.WasonS.J.EnrichC.RenteroC.Annexins–insights from knockout miceBiol. </plain></SENT>
<SENT sid="239" pm="."><plain>Chem.20163971031105310.1515/hsz-2016-0168<?supplied-pmid 27318360?>27318360 </plain></SENT>
</text></ref><ref id="B24-ijms-19-01781"><text><SENT sid="240" pm="."><plain>24.KenisH.van GenderenH.BennaghmouchA.RiniaH.A.FrederikP.NarulaJ.HofstraL.ReutelingspergerC.P.M.Cell surface-expressed phosphatidylserine and annexin A5 open a novel portal of cell entryJ. </plain></SENT>
<SENT sid="241" pm="."><plain>Biol. </plain></SENT>
<SENT sid="242" pm="."><plain>Chem.2004279526235262910.1074/jbc.M409009200<?supplied-pmid 15381697?>15381697 </plain></SENT>
</text></ref><ref id="B25-ijms-19-01781"><text><SENT sid="243" pm="."><plain>25.KenisH.HofstraL.ReutelingspergerC.P.M.Annexin A5: Shifting from a diagnostic towards a therapeutic realmCell. </plain></SENT>
<SENT sid="244" pm="."><plain>Mol. </plain></SENT>
<SENT sid="245" pm="."><plain>Life Sci.2007642859286210.1007/s00018-007-7297-2<?supplied-pmid 17876516?>17876516 </plain></SENT>
</text></ref><ref id="B26-ijms-19-01781"><text><SENT sid="246" pm="."><plain>26.AndreeH.A.ReutelingspergerC.P.HauptmannR.HemkerH.C.HermensW.T.WillemsG.M.Binding of vascular anticoagulant α (VAC α) to planar phospholipid bilayersJ. </plain></SENT>
<SENT sid="247" pm="."><plain>Biol. </plain></SENT>
<SENT sid="248" pm="."><plain>Chem.199026549234928<?supplied-pmid 2138622?>2138622 </plain></SENT>
</text></ref><ref id="B27-ijms-19-01781"><text><SENT sid="249" pm="."><plain>27.FadokV.A.VoelkerD.R.CampbellP.A.CohenJ.J.BrattonD.L.HensonP.M.Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophagesJ. </plain></SENT>
<SENT sid="250" pm="."><plain>Immunol.199214822072216<?supplied-pmid 1545126?>1545126 </plain></SENT>
</text></ref><ref id="B28-ijms-19-01781"><text><SENT sid="251" pm="."><plain>28.Van EngelandM.KuijpersH.J.H.RamaekersF.C.S.ReutelingspergerC.P.M.SchutteB.Plasma Membrane Alterations and Cytoskeletal Changes in ApoptosisExp. </plain></SENT>
<SENT sid="252" pm="."><plain>Cell Res.199723542143010.1006/excr.1997.3738<?supplied-pmid 9299167?>9299167 </plain></SENT>
</text></ref><ref id="B29-ijms-19-01781"><text><SENT sid="253" pm="."><plain>29.BoersmaH.H.KietselaerB.L.J.H.StolkL.M.L.BennaghmouchA.HofstraL.NarulaJ.HeidendalG.A.K.ReutelingspergerC.P.M.Past, present, and future of annexin A5: From protein discovery to clinical applicationsJ. </plain></SENT>
<SENT sid="254" pm="."><plain>Nucl. </plain></SENT>
<SENT sid="255" pm="."><plain>Med.20054620352050<?supplied-pmid 16330568?>16330568 </plain></SENT>
</text></ref><ref id="B30-ijms-19-01781"><text><SENT sid="256" pm="."><plain>30.NagataS.TanakaM.Programmed cell death and the immune systemNat. </plain></SENT>
<SENT sid="257" pm="."><plain>Rev. </plain></SENT>
<SENT sid="258" pm="."><plain>Immunol.20171733334010.1038/nri.2016.153<?supplied-pmid 28163302?>28163302 </plain></SENT>
</text></ref><ref id="B31-ijms-19-01781"><text><SENT sid="259" pm="."><plain>31.ArurS.UcheU.E.RezaulK.FongM.ScrantonV.CowanA.E.MohlerW.HanD.K.Annexin I is an endogenous ligand that mediates apoptotic cell engulfmentDev. </plain></SENT>
<SENT sid="260" pm="."><plain>Cell.2003458759810.1016/S1534-5807(03)00090-X12689596 </plain></SENT>
</text></ref><ref id="B32-ijms-19-01781"><text><SENT sid="261" pm="."><plain>32.PupjalisD.GoetschJ.KottasD.J.GerkeV.RescherU.Annexin A1 released from apoptotic cells acts through formyl peptide receptors to dampen inflammatory monocyte activation via JAK/STAT/SOCS signallingEMBO Mol. </plain></SENT>
<SENT sid="262" pm="."><plain>Med.2011310211410.1002/emmm.201000113<?supplied-pmid 21254404?>21254404 </plain></SENT>
</text></ref><ref id="B33-ijms-19-01781"><text><SENT sid="263" pm="."><plain>33.AsanoK.MiwaM.MiwaK.HanayamaR.NagaseH.NagataS.TanakaM.Masking of phosphatidylserine inhibits apoptotic cell engulfment and induces autoantibody production in miceJ. </plain></SENT>
<SENT sid="264" pm="."><plain>Exp. </plain></SENT>
<SENT sid="265" pm="."><plain>Med.200420045946710.1084/jem.20040342<?supplied-pmid 15302904?>15302904 </plain></SENT>
</text></ref><ref id="B34-ijms-19-01781"><text><SENT sid="266" pm="."><plain>34.BirgeR.B.BoeltzS.KumarS.CarlsonJ.WanderleyJ.CalianeseD.BarcinskiM.BrekkenR.A.HuangX.HutchinsJ.T.Phosphatidylserine is a global immunosuppressive signal in efferocytosis, infectious disease, and cancerCell Death Differ.20162396297810.1038/cdd.2016.11<?supplied-pmid 26915293?>26915293 </plain></SENT>
</text></ref><ref id="B35-ijms-19-01781"><text><SENT sid="267" pm="."><plain>35.SharmaB.KanwarS.S.Phosphatidylserine: A cancer cell targeting biomarkerSemin. </plain></SENT>
<SENT sid="268" pm="."><plain>Cancer Biol.201710.1016/j.semcancer.2017.08.012<?supplied-pmid 28870843?>28870843 </plain></SENT>
</text></ref><ref id="B36-ijms-19-01781"><text><SENT sid="269" pm="."><plain>36.OhP.LiY.YuJ.DurrE.KrasinskaK.M.CarverL.A.TestaJ.E.SchnitzerJ.E.Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapyNature200442962963510.1038/nature02580<?supplied-pmid 15190345?>15190345 </plain></SENT>
</text></ref><ref id="B37-ijms-19-01781"><text><SENT sid="270" pm="."><plain>37.PengB.GuoC.GuanH.LiuS.SunM.-Z.Annexin A5 as a potential marker in tumorsClin. </plain></SENT>
<SENT sid="271" pm="."><plain>Chim. </plain></SENT>
<SENT sid="272" pm="."><plain>Acta2014427424810.1016/j.cca.2013.09.048<?supplied-pmid 24121031?>24121031 </plain></SENT>
</text></ref><ref id="B38-ijms-19-01781"><text><SENT sid="273" pm="."><plain>38.LimaL.G.MonteiroR.Q.Activation of blood coagulation in cancer: Implications for tumour progressionBiosci. </plain></SENT>
<SENT sid="274" pm="."><plain>Rep.20133310.1042/BSR20130057<?supplied-pmid 23889169?>23889169 </plain></SENT>
</text></ref><ref id="B39-ijms-19-01781"><text><SENT sid="275" pm="."><plain>39.LentzB.R.Exposure of platelet membrane phosphatidylserine regulates blood coagulationProg. </plain></SENT>
<SENT sid="276" pm="."><plain>Lipid Res.20034242343810.1016/S0163-7827(03)00025-012814644 </plain></SENT>
</text></ref><ref id="B40-ijms-19-01781"><text><SENT sid="277" pm="."><plain>40.OrmesherL.GreerI.A.ANXA5: A key to unlock the mystery of the spectrum of placental-mediated pregnancy complications?Womens Health20161215916110.2217/whe-2015-0003<?supplied-pmid 26901843?>26901843 </plain></SENT>
</text></ref><ref id="B41-ijms-19-01781"><text><SENT sid="278" pm="."><plain>41.BogdanovaN.HorstJ.ChlystunM.CroucherP.J.P.NebelA.BohringA.TodorovaA.SchreiberS.GerkeV.KrawczakM.A common haplotype of the annexin A5 (ANXA5) gene promoter is associated with recurrent pregnancy lossHum. </plain></SENT>
<SENT sid="279" pm="."><plain>Mol. </plain></SENT>
<SENT sid="280" pm="."><plain>Genet.20071657357810.1093/hmg/ddm017<?supplied-pmid 17339269?>17339269 </plain></SENT>
</text></ref><ref id="B42-ijms-19-01781"><text><SENT sid="281" pm="."><plain>42.OlingF.Sopkova-DeJ.SantosO.GovorukhinaN.MazeC.Res-DubutÁ.Bergsma-SchutterW.OostergetelG.KeegstraW.LambertO.Structure of Membrane-bound Annexin A5 Trimers: A Hybrid Cryo-EM-X-ray Crystallography StudyJ. </plain></SENT>
<SENT sid="282" pm="."><plain>Mol. </plain></SENT>
<SENT sid="283" pm="."><plain>Biol.2000456157310.1006/jmbi.2000.4183<?supplied-pmid 11099380?>11099380 </plain></SENT>
</text></ref><ref id="B43-ijms-19-01781"><text><SENT sid="284" pm="."><plain>43.RandJ.H.WuX.LapinskiR.van HeerdeW.L.ReutelingspergerC.P.ChenP.P.OrtelT.L.Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndromeBlood20041042783279010.1182/blood-2004-01-0203<?supplied-pmid 15242878?>15242878 </plain></SENT>
</text></ref><ref id="B44-ijms-19-01781"><text><SENT sid="285" pm="."><plain>44.NegriniS.PappalardoF.MurdacaG.IndiveriF.PuppoF.The antiphospholipid syndrome: From pathophysiology to treatmentClin. </plain></SENT>
<SENT sid="286" pm="."><plain>Exp. </plain></SENT>
<SENT sid="287" pm="."><plain>Med.20171725726710.1007/s10238-016-0430-5<?supplied-pmid 27334977?>27334977 </plain></SENT>
</text></ref><ref id="B45-ijms-19-01781"><text><SENT sid="288" pm="."><plain>45.Rodríguez-GarcíaM.I.FernándezJ.A.RodríguezA.FernándezM.P.GutierrezC.Torre-AlonsoJ.C.Annexin V autoantibodies in rheumatoid arthritisAnn. </plain></SENT>
<SENT sid="289" pm="."><plain>Rheum. </plain></SENT>
<SENT sid="290" pm="."><plain>Dis.19965589590010.1136/ard.55.12.895<?supplied-pmid 9014583?>9014583 </plain></SENT>
</text></ref><ref id="B46-ijms-19-01781"><text><SENT sid="291" pm="."><plain>46.ScholzP.AulerM.BrachvogelB.BenzingT.MallmanP.StreichertT.KlattA.R.Detection of multiple annexin autoantibodies in a patient with recurrent miscarriages, fulminant stroke and seronegative antiphospholipid syndromeBiochem. </plain></SENT>
<SENT sid="292" pm="."><plain>Med.20162627227810.11613/BM.2016.032<?supplied-pmid 27346975?>27346975 </plain></SENT>
</text></ref><ref id="B47-ijms-19-01781"><text><SENT sid="293" pm="."><plain>47.KwonM.MacLeodT.J.ZhangY.WaismanD.S100A10, annexin A2, and annexin A2 heterotetramer as candidate plasminogen receptorsFront. </plain></SENT>
<SENT sid="294" pm="."><plain>Biosci.20051030032510.2741/1529<?supplied-pmid 15574370?>15574370 </plain></SENT>
</text></ref><ref id="B48-ijms-19-01781"><text><SENT sid="295" pm="."><plain>48.HajjarK.A.The Biology of Annexin A2: From Vascular Fibrinolysis to Innate ImmunityTrans. </plain></SENT>
<SENT sid="296" pm="."><plain>Am. </plain></SENT>
<SENT sid="297" pm="."><plain>Clin. </plain></SENT>
<SENT sid="298" pm="."><plain>Climatol. </plain></SENT>
<SENT sid="299" pm="."><plain>Assoc.2015126144155<?supplied-pmid 26330668?>26330668 </plain></SENT>
</text></ref><ref id="B49-ijms-19-01781"><text><SENT sid="300" pm="."><plain>49.LingQ.JacovinaA.T.DeoraA.FebbraioM.SimantovR.SilversteinR.L.HempsteadB.MarkW.H.HajjarK.A.Annexin II regulates fibrin homeostasis and neoangiogenesis in vivoJ. </plain></SENT>
<SENT sid="301" pm="."><plain>Clin. </plain></SENT>
<SENT sid="302" pm="."><plain>Invest.2004113384810.1172/JCI19684<?supplied-pmid 14702107?>14702107 </plain></SENT>
</text></ref><ref id="B50-ijms-19-01781"><text><SENT sid="303" pm="."><plain>50.MenellJ.S.CesarmanG.M.JacovinaA.T.McLaughlinM.A.LevE.A.HajjarK.A.Annexin II and Bleeding in Acute Promyelocytic LeukemiaN. </plain></SENT>
<SENT sid="304" pm="."><plain>Engl. </plain></SENT>
<SENT sid="305" pm="."><plain>J. </plain></SENT>
<SENT sid="306" pm="."><plain>Med.1999340994100410.1056/NEJM199904013401303<?supplied-pmid 10099141?>10099141 </plain></SENT>
</text></ref><ref id="B51-ijms-19-01781"><text><SENT sid="307" pm="."><plain>51.HannonR.CroxtallJ.D.GettingS.J.RoviezzoF.YonaS.Paul-ClarkM.J.GavinsF.N.E.PerrettiM.MorrisJ.F.BuckinghamJ.C.Aberrant inflammation and resistance to glucocorticoids in Annexin 1−/− MouseFASEB J.20021725325510.1096/fj.02-0239fje<?supplied-pmid 12475898?>12475898 </plain></SENT>
</text></ref><ref id="B52-ijms-19-01781"><text><SENT sid="308" pm="."><plain>52.VongL.D’AcquistoF.Pederzoli-RibeilM.LavagnoL.FlowerR.J.Witko-SarsatV.PerrettiM.Annexin 1 cleavage in activated neutrophils: A pivotal role for proteinase 3J. </plain></SENT>
<SENT sid="309" pm="."><plain>Biol. </plain></SENT>
<SENT sid="310" pm="."><plain>Chem.2007282299983000410.1074/jbc.M702876200<?supplied-pmid 17681950?>17681950 </plain></SENT>
</text></ref><ref id="B53-ijms-19-01781"><text><SENT sid="311" pm="."><plain>53.PerrettiM.DalliJ.Exploiting the Annexin A1 pathway for the development of novel anti-inflammatory therapeuticsBr. </plain></SENT>
<SENT sid="312" pm="."><plain>J. </plain></SENT>
<SENT sid="313" pm="."><plain>Pharmacol.200915893694610.1111/j.1476-5381.2009.00483.x<?supplied-pmid 19845684?>19845684 </plain></SENT>
</text></ref><ref id="B54-ijms-19-01781"><text><SENT sid="314" pm="."><plain>54.PerrettiM.D’AcquistoF.Annexin A1 and glucocorticoids as effectors of the resolution of inflammationNat. </plain></SENT>
<SENT sid="315" pm="."><plain>Rev. </plain></SENT>
<SENT sid="316" pm="."><plain>Immunol.20099627010.1038/nri2470<?supplied-pmid 19104500?>19104500 </plain></SENT>
</text></ref><ref id="B55-ijms-19-01781"><text><SENT sid="317" pm="."><plain>55.KamalA.M.FlowerR.J.PerrettiM.An overview of the effects of annexin 1 on cells involved in the inflammatory processMem. </plain></SENT>
<SENT sid="318" pm="."><plain>Inst. </plain></SENT>
<SENT sid="319" pm="."><plain>Oswaldo Cruz2005100394810.1590/S0074-02762005000900008<?supplied-pmid 15962097?>15962097 </plain></SENT>
</text></ref><ref id="B56-ijms-19-01781"><text><SENT sid="320" pm="."><plain>56.DuftonN.PerrettiM.Therapeutic anti-inflammatory potential of formyl-peptide receptor agonistsPharmacol. </plain></SENT>
<SENT sid="321" pm="."><plain>Ther.201012717518810.1016/j.pharmthera.2010.04.010<?supplied-pmid 20546777?>20546777 </plain></SENT>
</text></ref><ref id="B57-ijms-19-01781"><text><SENT sid="322" pm="."><plain>57.HayhoeR.P.G.KamalA.M.SolitoE.FlowerR.J.CooperD.PerrettiM.Annexin 1 and its bioactive peptide inhibit neutrophil-endothelium interactions under flow: Indication of distinct receptor involvementBlood20061072123213010.1182/blood-2005-08-3099<?supplied-pmid 16278303?>16278303 </plain></SENT>
</text></ref><ref id="B58-ijms-19-01781"><text><SENT sid="323" pm="."><plain>58.ErnstS.LangeC.WilbersA.GoebelerV.GerkeV.RescherU.An annexin 1 N-terminal peptide activates leukocytes by triggering different members of the formyl peptide receptor familyJ. </plain></SENT>
<SENT sid="324" pm="."><plain>Immunol.20041727669767610.4049/jimmunol.172.12.7669<?supplied-pmid 15187149?>15187149 </plain></SENT>
</text></ref><ref id="B59-ijms-19-01781"><text><SENT sid="325" pm="."><plain>59.WeydH.More than just innate affairs–on the role of annexins in adaptive immunityBiol. </plain></SENT>
<SENT sid="326" pm="."><plain>Chem.20163971017102910.1515/hsz-2016-0191<?supplied-pmid 27467753?>27467753 </plain></SENT>
</text></ref><ref id="B60-ijms-19-01781"><text><SENT sid="327" pm="."><plain>60.YeR.D.BoulayF.WangJ.M.DahlgrenC.GerardC.ParmentierM.SerhanC.N.MurphyP.M.International Union of Basic and Clinical Pharmacology. </plain></SENT>
<SENT sid="328" pm="."><plain>LXXIII. </plain></SENT>
<SENT sid="329" pm="."><plain>Nomenclature for the formyl peptide receptor (FPR) familyPharmacol. </plain></SENT>
<SENT sid="330" pm="."><plain>Rev.20096111916110.1124/pr.109.001578<?supplied-pmid 19498085?>19498085 </plain></SENT>
</text></ref><ref id="B61-ijms-19-01781"><text><SENT sid="331" pm="."><plain>61.LeY.MurphyP.M.WangJ.M.Formyl-peptide receptors revisitedTrends Immunol.20022354154810.1016/S1471-4906(02)02316-512401407 </plain></SENT>
</text></ref><ref id="B62-ijms-19-01781"><text><SENT sid="332" pm="."><plain>62.RescherU.DanielczykA.MarkoffA.GerkeV.Functional activation of the formyl peptide receptor by a new endogenous ligand in human lung A549 cellsJ. </plain></SENT>
<SENT sid="333" pm="."><plain>Immunol.20021691500150410.4049/jimmunol.169.3.1500<?supplied-pmid 12133977?>12133977 </plain></SENT>
</text></ref><ref id="B63-ijms-19-01781"><text><SENT sid="334" pm="."><plain>63.HeH.-Q.YeR.The Formyl Peptide Receptors: Diversity of Ligands and Mechanism for RecognitionMolecules20172245510.3390/molecules22030455<?supplied-pmid 28335409?>28335409 </plain></SENT>
</text></ref><ref id="B64-ijms-19-01781"><text><SENT sid="335" pm="."><plain>64.VongL.FerrazJ.G.P.DuftonN.PanaccioneR.BeckP.L.ShermanP.M.PerrettiM.WallaceJ.L.Up-Regulation of Annexin-A1 and Lipoxin A 4 in Individuals with Ulcerative Colitis May Promote Mucosal HomeostasisPLoS ONE20127e3924410.1371/journal.pone.0039244<?supplied-pmid 22723974?>22723974 </plain></SENT>
</text></ref><ref id="B65-ijms-19-01781"><text><SENT sid="336" pm="."><plain>65.LeoniG.AlamA.NeumannP.LambethJ.D.ChengG.McCoyJ.HilgarthR.S.KunduK.MurthyN.KustersD.Annexin A1, formyl peptide receptor, and NOX1 orchestrate epithelial repairJ. </plain></SENT>
<SENT sid="337" pm="."><plain>Clin. </plain></SENT>
<SENT sid="338" pm="."><plain>Invest.201312344345410.1172/JCI65831<?supplied-pmid 23241962?>23241962 </plain></SENT>
</text></ref><ref id="B66-ijms-19-01781"><text><SENT sid="339" pm="."><plain>66.LeoniG.NeumannP.A.KamalyN.QuirosM.NishioH.JonesH.R.SumaginR.HilgarthR.S.AlamA.FredmanG.Annexin A1-containing extracellular vesicles and polymeric nanoparticles promote epithelial wound repairJ. </plain></SENT>
<SENT sid="340" pm="."><plain>Clin. </plain></SENT>
<SENT sid="341" pm="."><plain>Invest.201510.1172/JCI76693<?supplied-pmid 25664854?>25664854 </plain></SENT>
</text></ref><ref id="B67-ijms-19-01781"><text><SENT sid="342" pm="."><plain>67.OuyangN.ZhuC.ZhouD.NieT.GoM.F.RichardsR.J.RigasB.MC-12, an Annexin A1-Based Peptide, Is Effective in the Treatment of Experimental ColitisPLoS ONE20127e4158510.1371/journal.pone.0041585<?supplied-pmid 22844504?>22844504 </plain></SENT>
</text></ref><ref id="B68-ijms-19-01781"><text><SENT sid="343" pm="."><plain>68.KosickaA.CunliffeA.D.MackenzieR.ZariwalaM.G.PerrettiM.FlowerR.J.RenshawD.Attenuation of plasma annexin A1 in human obesityFASEB J.20132736837810.1096/fj.12-213728<?supplied-pmid 23038751?>23038751 </plain></SENT>
</text></ref><ref id="B69-ijms-19-01781"><text><SENT sid="344" pm="."><plain>69.AkashehR.T.PiniM.PangJ.FantuzziG.Increased adiposity in annexin A1-deficient micePLoS ONE20138e8260810.1371/journal.pone.0082608<?supplied-pmid 24312665?>24312665 </plain></SENT>
</text></ref><ref id="B70-ijms-19-01781"><text><SENT sid="345" pm="."><plain>70.YoonJ.H.KimD.JangJ.GhimJ.ParkS.SongP.KwonY.KimJ.HwangD.BaeY.Proteomic analysis of the palmitate-induced myotube secretome reveals involvement of the annexin A1-formyl peptide receptor 2 (FPR2) pathway in insulin resistanceMol. </plain></SENT>
<SENT sid="346" pm="."><plain>Cell. </plain></SENT>
<SENT sid="347" pm="."><plain>Proteom.20151488289210.1074/mcp.M114.039651<?supplied-pmid 25616869?>25616869 </plain></SENT>
</text></ref><ref id="B71-ijms-19-01781"><text><SENT sid="348" pm="."><plain>71.CheukB.L.Y.ChengS.W.K.Annexin A1 expression in atherosclerotic carotid plaques and its relationship with plaque characteristicsEur. </plain></SENT>
<SENT sid="349" pm="."><plain>J. </plain></SENT>
<SENT sid="350" pm="."><plain>Vasc. </plain></SENT>
<SENT sid="351" pm="."><plain>Endovasc. </plain></SENT>
<SENT sid="352" pm="."><plain>Surg.20114136437110.1016/j.ejvs.2010.11.021<?supplied-pmid 21195640?>21195640 </plain></SENT>
</text></ref><ref id="B72-ijms-19-01781"><text><SENT sid="353" pm="."><plain>72.FredmanG.HellmannJ.ProtoJ.D.KuriakoseG.ColasR.A.DorweilerB.ConnollyE.S.SolomonR.JonesD.M.HeyerE.J.An imbalance between specialized pro-resolving lipid mediators and pro-inflammatory leukotrienes promotes instability of atherosclerotic plaquesNat. </plain></SENT>
<SENT sid="354" pm="."><plain>Commun.201671285910.1038/ncomms12859<?supplied-pmid 27659679?>27659679 </plain></SENT>
</text></ref><ref id="B73-ijms-19-01781"><text><SENT sid="355" pm="."><plain>73.KrishnamoorthyS.RecchiutiA.ChiangN.FredmanG.SerhanC.N.Resolvin D1 receptor stereoselectivity and regulation of inflammation and proresolving microRNAsAm. </plain></SENT>
<SENT sid="356" pm="."><plain>J. </plain></SENT>
<SENT sid="357" pm="."><plain>Pathol.20121802018202710.1016/j.ajpath.2012.01.028<?supplied-pmid 22449948?>22449948 </plain></SENT>
</text></ref><ref id="B74-ijms-19-01781"><text><SENT sid="358" pm="."><plain>74.SolitoE.McArthurS.ChristianH.GavinsF.BuckinghamJ.C.GilliesG.E.Annexin A1 in the brain—Undiscovered roles?Trends Pharmacol. </plain></SENT>
<SENT sid="359" pm="."><plain>Sci.20082913514210.1016/j.tips.2007.12.003<?supplied-pmid 18262660?>18262660 </plain></SENT>
</text></ref><ref id="B75-ijms-19-01781"><text><SENT sid="360" pm="."><plain>75.DörrA.KressE.PodschunR.PufeT.TauberS.C.BrandenburgL.Intrathecal application of the antimicrobial peptide CRAMP reduced mortality and neuroinflammation in an experimental model of pneumococcal meningitisJ. </plain></SENT>
<SENT sid="361" pm="."><plain>Infect.20157118819910.1016/j.jinf.2015.04.006<?supplied-pmid 25896094?>25896094 </plain></SENT>
</text></ref><ref id="B76-ijms-19-01781"><text><SENT sid="362" pm="."><plain>76.GavinsF.N.E.DalliJ.FlowerR.J.GrangerD.N.PerrettiM.Activation of the annexin 1 counter-regulatory circuit affords protection in the mouse brain microcirculationFASEB J.2007211751175810.1096/fj.06-7842com<?supplied-pmid 17317721?>17317721 </plain></SENT>
</text></ref><ref id="B77-ijms-19-01781"><text><SENT sid="363" pm="."><plain>77.VitalS.A.BeckerF.HollowayP.M.RussellJ.PerrettiM.GrangerD.N.GavinsF.N.E.Formyl-Peptide Receptor 2/3/Lipoxin A4 Receptor Regulates Neutrophil-Platelet Aggregation and Attenuates Cerebral Inflammation: Impact for Therapy in Cardiovascular DiseaseCirculation20161332169217910.1161/CIRCULATIONAHA.115.020633<?supplied-pmid 27154726?>27154726 </plain></SENT>
</text></ref><ref id="B78-ijms-19-01781"><text><SENT sid="364" pm="."><plain>78.DamazoA.S.YonaS.D’AcquistoF.FlowerR.J.OlianiS.M.PerrettiM.Critical protective role for annexin 1 gene expression in the endotoxemic murine microcirculationAm. </plain></SENT>
<SENT sid="365" pm="."><plain>J. </plain></SENT>
<SENT sid="366" pm="."><plain>Pathol.20051661607161710.1016/S0002-9440(10)62471-615920146 </plain></SENT>
</text></ref><ref id="B79-ijms-19-01781"><text><SENT sid="367" pm="."><plain>79.TsaiW.LiI.YuY.HsuH.ShihC.Serial Changes in Plasma Annexin A1 and Cortisol Levels in Sepsis PatientsChin. </plain></SENT>
<SENT sid="368" pm="."><plain>J. </plain></SENT>
<SENT sid="369" pm="."><plain>Physiol.2014571710.4077/CJP.2014.BAB193<?supplied-pmid 24621333?>24621333 </plain></SENT>
</text></ref><ref id="B80-ijms-19-01781"><text><SENT sid="370" pm="."><plain>80.WestM.A.HeagyW.Endotoxin tolerance: A reviewCrit. </plain></SENT>
<SENT sid="371" pm="."><plain>Care Med.200230S64S7310.1097/00003246-200201001-00009<?supplied-pmid 11891406?>11891406 </plain></SENT>
</text></ref><ref id="B81-ijms-19-01781"><text><SENT sid="372" pm="."><plain>81.SwisherJ.F.A.BurtonN.BacotS.M.VogelS.N.FeldmanG.M.Annexin A2 tetramer activates human and murine macrophages through TLR4Blood201011554955810.1182/blood-2009-06-226944<?supplied-pmid 19965653?>19965653 </plain></SENT>
</text></ref><ref id="B82-ijms-19-01781"><text><SENT sid="373" pm="."><plain>82.SwisherJ.F.A.KhatriU.FeldmanG.M.Annexin A2 is a soluble mediator of macrophage activationJ. </plain></SENT>
<SENT sid="374" pm="."><plain>Leukoc. </plain></SENT>
<SENT sid="375" pm="."><plain>Biol.2007821174118410.1189/jlb.0307154<?supplied-pmid 17715360?>17715360 </plain></SENT>
</text></ref><ref id="B83-ijms-19-01781"><text><SENT sid="376" pm="."><plain>83.ZhangS.YuM.GuoQ.LiR.LiG.TanS.LiX.WeiY.WuM.Annexin A2 binds to endosomes and negatively regulates TLR4-triggered inflammatory responses via the TRAM-TRIF pathwaySci. </plain></SENT>
<SENT sid="377" pm="."><plain>Rep.201551585910.1038/srep15859<?supplied-pmid 26527544?>26527544 </plain></SENT>
</text></ref><ref id="B84-ijms-19-01781"><text><SENT sid="378" pm="."><plain>84.AndersenB.M.XiaJ.EpsteinA.L.OhlfestJ.R.ChenW.BlazarB.R.PennellC.A.OlinM.R.Monomeric annexin A2 is an oxygen-regulated toll-like receptor 2 ligand and adjuvantJ. </plain></SENT>
<SENT sid="379" pm="."><plain>Immunother. </plain></SENT>
<SENT sid="380" pm="."><plain>Cancer201641810.1186/s40425-016-0112-6<?supplied-pmid 26885373?>26885373 </plain></SENT>
</text></ref><ref id="B85-ijms-19-01781"><text><SENT sid="381" pm="."><plain>85.SeidahN.G.PoirierS.DenisM.ParkerR.MiaoB.MapelliC.PratA.WassefH.DavignonJ.HajjarK.A.Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradationPLoS ONE20127e4186510.1371/journal.pone.0041865<?supplied-pmid 22848640?>22848640 </plain></SENT>
</text></ref><ref id="B86-ijms-19-01781"><text><SENT sid="382" pm="."><plain>86.LyK.SaavedraY.G.L.CanuelM.RouthierS.DesjardinsR.HamelinJ.MayneJ.LazureC.SeidahN.G.DayR.Annexin A2 reduces PCSK9 protein levels via a translational mechanism and interacts with the M1 and M2 domains of PCSK9J. </plain></SENT>
<SENT sid="383" pm="."><plain>Biol. </plain></SENT>
<SENT sid="384" pm="."><plain>Chem.2014289177321774610.1074/jbc.M113.541094<?supplied-pmid 24808179?>24808179 </plain></SENT>
</text></ref><ref id="B87-ijms-19-01781"><text><SENT sid="385" pm="."><plain>87.MayerG.PoirierS.SeidahN.G.Annexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levelsJ. </plain></SENT>
<SENT sid="386" pm="."><plain>Biol. </plain></SENT>
<SENT sid="387" pm="."><plain>Chem.2008283317913180110.1074/jbc.M805971200<?supplied-pmid 18799458?>18799458 </plain></SENT>
</text></ref><ref id="B88-ijms-19-01781"><text><SENT sid="388" pm="."><plain>88.TakahashiS.ReddyS.V.ChirgwinJ.M.DevlinR.HaipekC.AndersonJ.RoodmanG.D.Cloning and identification of annexin II as an autocrine/paracrine factor that increases osteoclast formation and bone resorptionJ. </plain></SENT>
<SENT sid="389" pm="."><plain>Biol. </plain></SENT>
<SENT sid="390" pm="."><plain>Chem.19942692869628701<?supplied-pmid 7961821?>7961821 </plain></SENT>
</text></ref><ref id="B89-ijms-19-01781"><text><SENT sid="391" pm="."><plain>89.LiF.ChungH.ReddyS.V.LuG.KuriharaN.ZhaoA.Z.RoodmanG.D.Annexin II Stimulates RANKL Expression Through MAPKJ. </plain></SENT>
<SENT sid="392" pm="."><plain>Bone Miner. </plain></SENT>
<SENT sid="393" pm="."><plain>Res.2005201161116710.1359/JBMR.050207<?supplied-pmid 15940368?>15940368 </plain></SENT>
</text></ref><ref id="B90-ijms-19-01781"><text><SENT sid="394" pm="."><plain>90.LuG.MaedaH.ReddyS.V.KuriharaN.LeachR.AndersonJ.L.RoodmanG.D.Cloning and characterization of the annexin II receptor on human marrow stromal cellsJ. </plain></SENT>
<SENT sid="395" pm="."><plain>Biol. </plain></SENT>
<SENT sid="396" pm="."><plain>Chem.2006281305423055010.1074/jbc.M607072200<?supplied-pmid 16895901?>16895901 </plain></SENT>
</text></ref><ref id="B91-ijms-19-01781"><text><SENT sid="397" pm="."><plain>91.PandeyS.RanjanR.PandeyS.MishraR.M.SethT.SaxenaR.Effect of ANXA2 gene single nucleotide polymorphism (SNP) on the development of osteonecrosis in Indian sickle cell patient: A PCR-RFLP approachIndian J. Exp. </plain></SENT>
<SENT sid="399" pm="."><plain>Biol.201250455458<?supplied-pmid 22822523?>22822523 </plain></SENT>
</text></ref><ref id="B92-ijms-19-01781"><text><SENT sid="400" pm="."><plain>92.D’SouzaS.KuriharaN.ShiozawaY.JosephJ.TaichmanR.GalsonD.L.RoodmanG.D.Annexin II interactions with the annexin II receptor enhance multiple myeloma cell adhesion and growth in the bone marrow microenvironmentBlood20121191888189610.1182/blood-2011-11-393348<?supplied-pmid 22223826?>22223826 </plain></SENT>
</text></ref><ref id="B93-ijms-19-01781"><text><SENT sid="401" pm="."><plain>93.PerucciL.O.SugimotoM.A.GomesK.B.DusseL.M.TeixeiraM.M.SousaL.P.Annexin A1 and specialized proresolving lipid mediators: Promoting resolution as a therapeutic strategy in human inflammatory diseasesExpert Opin. </plain></SENT>
<SENT sid="402" pm="."><plain>Ther. </plain></SENT>
<SENT sid="403" pm="."><plain>Targets20172187989610.1080/14728222.2017.1364363<?supplied-pmid 28786708?>28786708 </plain></SENT>
</text></ref><ref id="B94-ijms-19-01781"><text><SENT sid="404" pm="."><plain>94.HiramotoH.DansakoH.TakedaM.SatohS.WakitaT.IkedaM.KatoN.Annexin A1 negatively regulates viral RNA replication of hepatitis C virusActa Med. </plain></SENT>
<SENT sid="405" pm="."><plain>Okayama2015697178<?supplied-pmid 25899628?>25899628 </plain></SENT>
</text></ref><ref id="B95-ijms-19-01781"><text><SENT sid="406" pm="."><plain>95.AroraS.LimW.BistP.PerumalsamyR.LukmanH.M.LiF.WelkerL.B.YanB.SethiG.TambyahP.A.Influenza A virus enhances its propagation through the modulation of Annexin-A1 dependent endosomal trafficking and apoptosisCell Death Differ.2016231243125610.1038/cdd.2016.19<?supplied-pmid 26943321?>26943321 </plain></SENT>
</text></ref><ref id="B96-ijms-19-01781"><text><SENT sid="407" pm="."><plain>96.PaudelN.SadagopanS.BalasubramanianS.ChandranB.Kaposi’s Sarcoma-Associated Herpesvirus Latency-Associated Nuclear Antigen and Angiogenin Interact with Common Host Proteins, Including Annexin A2, Which Is Essential for Survival of Latently Infected CellsJ. </plain></SENT>
<SENT sid="408" pm="."><plain>Virol.2012861589160710.1128/JVI.05754-11<?supplied-pmid 22130534?>22130534 </plain></SENT>
</text></ref><ref id="B97-ijms-19-01781"><text><SENT sid="409" pm="."><plain>97.LuoW.YanG.LiL.WangZ.LiuH.ZhouS.LiuS.TangM.YiW.DongZ.Epstein-Barr virus latent membrane protein 1 mediates serine 25 phosphorylation and nuclear entry of annexin A2 via PI-PLC-PKCα/PKCβ pathwayMol. </plain></SENT>
<SENT sid="410" pm="."><plain>Carcinog.20084793494610.1002/mc.20445<?supplied-pmid 18412141?>18412141 </plain></SENT>
</text></ref><ref id="B98-ijms-19-01781"><text><SENT sid="411" pm="."><plain>98.CalmonM.F.MotaM.T.D.BabetoÉ.CandidoN.M.GirolA.P.MendiburuC.F.BonilhaJ.L.SilvestreR.V.D.RosaB.M.ThoméJ.A.Overexpression of ANXA1 in Penile Carcinomas Positive for High-Risk HPVsPLoS ONE20138e5326010.1371/journal.pone.0053260<?supplied-pmid 23341933?>23341933 </plain></SENT>
</text></ref><ref id="B99-ijms-19-01781"><text><SENT sid="412" pm="."><plain>99.GanH.LeeJ.RenF.ChenM.KornfeldH.RemoldH.G.Mycobacterium tuberculosis blocks crosslinking of annexin-1 and apoptotic envelope formation on infected macrophages to maintain virulenceNat. </plain></SENT>
<SENT sid="413" pm="."><plain>Immunol.200891189119710.1038/ni.1654<?supplied-pmid 18794848?>18794848 </plain></SENT>
</text></ref><ref id="B100-ijms-19-01781"><text><SENT sid="414" pm="."><plain>100.RongB.ZhaoC.LiuH.MingZ.CaiX.GaoW.YangS.Elevated serum annexin A1 as potential diagnostic marker for lung cancer: A retrospective case-control studyAm. </plain></SENT>
<SENT sid="415" pm="."><plain>J. </plain></SENT>
<SENT sid="416" pm="."><plain>Transl. </plain></SENT>
<SENT sid="417" pm="."><plain>Res.20146558569<?supplied-pmid 25360220?>25360220 </plain></SENT>
</text></ref><ref id="B101-ijms-19-01781"><text><SENT sid="418" pm="."><plain>101.VoigtT.SebaldH.SchoenauerR.LevanoS.GirardT.HoppelerH.H.BabiychukE.B.DraegerA.Annexin A1 is a biomarker of T-tubular repair in skeletal muscle of nonmyopathic patients undergoing statin therapyFASEB J.2013272156216410.1096/fj.12-219345<?supplied-pmid 23413360?>23413360 </plain></SENT>
</text></ref><ref id="B102-ijms-19-01781"><text><SENT sid="419" pm="."><plain>102.LuoS.XieC.WuP.HeJ.TangY.XuJ.ZhaoS.Annexin A2 is an independent prognostic biomarker for evaluating the malignant progression of laryngeal cancerExp. </plain></SENT>
<SENT sid="420" pm="."><plain>Ther. </plain></SENT>
<SENT sid="421" pm="."><plain>Med.2017146113611810.3892/etm.2017.5298<?supplied-pmid 29285166?>29285166 </plain></SENT>
</text></ref><ref id="B103-ijms-19-01781"><text><SENT sid="422" pm="."><plain>103.LiuS.LinC.PengS.JengY.PanH.LaiP.LiuC.HsuH.Down-Regulation of Annexin A10 in Hepatocellular Carcinoma Is Associated with Vascular Invasion, Early Recurrence, and Poor Prognosis in Synergy with p53 MutationAm. </plain></SENT>
<SENT sid="423" pm="."><plain>J. </plain></SENT>
<SENT sid="424" pm="."><plain>Pathol.20021601831183710.1016/S0002-9440(10)61129-712000734 </plain></SENT>
</text></ref><ref id="B104-ijms-19-01781"><text><SENT sid="425" pm="."><plain>104.LuS.YuanR.ChenY.HsuH.JengY.Annexin A10 is an immunohistochemical marker for adenocarcinoma of the upper gastrointestinal tract and pancreatobiliary systemHistopathology20136364064810.1111/his.12229<?supplied-pmid 24024557?>24024557 </plain></SENT>
</text></ref><ref id="B105-ijms-19-01781"><text><SENT sid="426" pm="."><plain>105.PatelM.I.SinghJ.NiknamiM.KurekC.YaoM.LuS.MacleanF.KingN.J.C.GelbM.H.ScottK.F.Cytosolic phospholipase A2-α: A potential therapeutic target for prostate cancerClin. </plain></SENT>
<SENT sid="427" pm="."><plain>Cancer Res.2008148070807910.1158/1078-0432.CCR-08-0566<?supplied-pmid 19088022?>19088022 </plain></SENT>
</text></ref><ref id="B106-ijms-19-01781"><text><SENT sid="428" pm="."><plain>106.KimS.W.RheeH.J.KoJ.KimY.J.KimH.G.YangJ.M.ChoiE.C.NaD.S.Inhibition of cytosolic phospholipase A2 by annexin I. Specific interaction model and mapping of the interaction siteJ. </plain></SENT>
<SENT sid="430" pm="."><plain>Biol. </plain></SENT>
<SENT sid="431" pm="."><plain>Chem.2001276157121571910.1074/jbc.M009905200<?supplied-pmid 11278580?>11278580 </plain></SENT>
</text></ref><ref id="B107-ijms-19-01781"><text><SENT sid="432" pm="."><plain>107.KimS.KoJ.KimJ.H.ChoiE.C.NaD.S.Differential effects of annexins I, II, III, and V on cytosolic phospholipase A2 activity: Specific interaction modelFEBS Lett.200148924324810.1016/S0014-5793(00)02326-711165258 </plain></SENT>
</text></ref><ref id="B108-ijms-19-01781"><text><SENT sid="433" pm="."><plain>108.KimK.M.KimD.K.ParkY.M.KimC.K.NaD.S.Annexin-I inhibits phospholipase A2 by specific interaction, not by substrate depletionFEBS Lett.199434325125510.1016/0014-5793(94)80566-08174710 </plain></SENT>
</text></ref><ref id="B109-ijms-19-01781"><text><SENT sid="434" pm="."><plain>109.van de GraafS.F.J.HoenderopJ.G.J.GkikaD.LamersD.PrenenJ.RescherU.GerkeV.StaubO.NiliusB.BindelsR.J.M.Functional expression of the epithelial Ca2+ channels (TRPV5 and TRPV6) requires association of the S100A10-annexin 2 complexEMBO J.2003221478148710.1093/emboj/cdg162<?supplied-pmid 12660155?>12660155 </plain></SENT>
</text></ref><ref id="B110-ijms-19-01781"><text><SENT sid="435" pm="."><plain>110.DonierE.RugieroF.OkuseK.WoodJ.N.Annexin II Light Chain p11 Promotes Functional Expression of Acid-sensing Ion Channel ASIC1aJ. </plain></SENT>
<SENT sid="436" pm="."><plain>Biol. </plain></SENT>
<SENT sid="437" pm="."><plain>Chem.2005280386663867210.1074/jbc.M505981200<?supplied-pmid 16169854?>16169854 </plain></SENT>
</text></ref><ref id="B111-ijms-19-01781"><text><SENT sid="438" pm="."><plain>111.GirardC.TinelN.TerrenoireC.RomeyG.LazdunskiM.BorsottoM.p11, an annexin II subunit, an auxiliary protein associated with the background K+ channel, TASK-1EMBO J.2002214439444810.1093/emboj/cdf469<?supplied-pmid 12198146?>12198146 </plain></SENT>
</text></ref><ref id="B112-ijms-19-01781"><text><SENT sid="439" pm="."><plain>112.MuimoR.Regulation of CFTR function by annexin A2-S100A10 complex in health and diseaseGen. </plain></SENT>
<SENT sid="440" pm="."><plain>Physiol. </plain></SENT>
<SENT sid="441" pm="."><plain>Biophys.2009281419 </plain></SENT>
</text></ref><ref id="B113-ijms-19-01781"><text><SENT sid="442" pm="."><plain>113.HessnerF.DlugosC.P.ChehabT.SchaeferC.HomeyB.GerkeV.WeideT.PavenstädtH.RescherU.CC chemokine receptor 10 cell surface presentation in melanocytes is regulated by the novel interaction partner S100A10Sci. </plain></SENT>
<SENT sid="443" pm="."><plain>Rep.201662264910.1038/srep22649<?supplied-pmid 26941067?>26941067 </plain></SENT>
</text></ref><ref id="B114-ijms-19-01781"><text><SENT sid="444" pm="."><plain>114.SvenningssonP.CherguiK.RachleffI.FlajoletM.ZhangX.el YacoubiM.VaugeoisJ.NomikosG.G.GreengardP.Alterations in 5-HT1B Receptor Function by p11 in Depression-Like StatesScience2006311778010.1126/science.1117571<?supplied-pmid 16400147?>16400147 </plain></SENT>
</text></ref><ref id="B115-ijms-19-01781"><text><SENT sid="445" pm="."><plain>115.GrewalT.HoqueM.ConwayJ.R.W.ReverterM.WahbaM.BeeviS.S.TimpsonP.EnrichC.RenteroC.Annexin A6-A multifunctional scaffold in cell motilityCell Adh. </plain></SENT>
<SENT sid="446" pm="."><plain>Migr.20171128830410.1080/19336918.2016.1268318<?supplied-pmid 28060548?>28060548 </plain></SENT>
</text></ref><ref id="B116-ijms-19-01781"><text><SENT sid="447" pm="."><plain>116.HeitzigN.BrinkmannB.F.KoerdtS.N.RossoG.ShahinV.RescherU.Annexin A8 promotes VEGF-A driven endothelial cell sproutingCell Adh. </plain></SENT>
<SENT sid="448" pm="."><plain>Migr.20171127528710.1080/19336918.2016.1264559<?supplied-pmid 28060564?>28060564 </plain></SENT>
</text></ref><ref id="B117-ijms-19-01781"><text><SENT sid="449" pm="."><plain>117.PoeterM.RadkeS.KoeseM.HessnerF.HegemannA.MusiolA.GerkeV.GrewalT.RescherU.Disruption of the annexin A1/S100A11 complex increases the migration and clonogenic growth by dysregulating epithelial growth factor (EGF) signalingBiochim. </plain></SENT>
<SENT sid="450" pm="."><plain>Biophys. </plain></SENT>
<SENT sid="451" pm="."><plain>Acta201318331700171110.1016/j.bbamcr.2012.12.006<?supplied-pmid 23246849?>23246849 </plain></SENT>
</text></ref><ref id="B118-ijms-19-01781"><text><SENT sid="452" pm="."><plain>118.TatenhorstL.RescherU.GerkeV.PaulusW.Knockdown of annexin 2 decreases migration of human glioma cells in vitroNeuropathol. </plain></SENT>
<SENT sid="453" pm="."><plain>Appl. </plain></SENT>
<SENT sid="454" pm="."><plain>Neurobiol.20063227127710.1111/j.1365-2990.2006.00720.x<?supplied-pmid 16640645?>16640645 </plain></SENT>
</text></ref><ref id="B119-ijms-19-01781"><text><SENT sid="455" pm="."><plain>119.RescherU.LudwigC.KonietzkoV.KharitonenkovA.GerkeV.Tyrosine phosphorylation of annexin A2 regulates Rho-mediated actin rearrangement and cell adhesionJ. </plain></SENT>
<SENT sid="456" pm="."><plain>Cell Sci.20081212177218510.1242/jcs.028415<?supplied-pmid 18565825?>18565825 </plain></SENT>
</text></ref><ref id="B120-ijms-19-01781"><text><SENT sid="457" pm="."><plain>120.QuiskampN.PoeterM.RaabeC.A.HohenesterU.M.KönigS.GerkeV.RescherU.The tumor suppressor annexin A10 is a novel component of nuclear paraspecklesCell. </plain></SENT>
<SENT sid="458" pm="."><plain>Mol. </plain></SENT>
<SENT sid="459" pm="."><plain>Life Sci.20147131132910.1007/s00018-013-1375-4<?supplied-pmid 23715859?>23715859 </plain></SENT>
</text></ref><ref id="B121-ijms-19-01781"><text><SENT sid="460" pm="."><plain>121.HanR.CampbellK.P.Dysferlin and muscle membrane repairCurr. </plain></SENT>
<SENT sid="461" pm="."><plain>Opin. </plain></SENT>
<SENT sid="462" pm="."><plain>Cell Biol.20071940941610.1016/j.ceb.2007.07.001<?supplied-pmid 17662592?>17662592 </plain></SENT>
</text></ref><ref id="B122-ijms-19-01781"><text><SENT sid="463" pm="."><plain>122.DraegerA.MonastyrskayaK.BabiychukE.B.Plasma membrane repair and cellular damage control: The annexin survival kitBiochem. </plain></SENT>
<SENT sid="464" pm="."><plain>Pharmacol.20118170371210.1016/j.bcp.2010.12.027<?supplied-pmid 21219882?>21219882 </plain></SENT>
</text></ref><ref id="B123-ijms-19-01781"><text><SENT sid="465" pm="."><plain>123.LauritzenS.P.BoyeT.L.NylandstedJ.Annexins are instrumental for efficient plasma membrane repair in cancer cellsSemin. </plain></SENT>
<SENT sid="466" pm="."><plain>Cell Dev. </plain></SENT>
<SENT sid="467" pm="."><plain>Biol.201545323810.1016/j.semcdb.2015.10.028<?supplied-pmid 26498035?>26498035 </plain></SENT>
</text></ref><ref id="B124-ijms-19-01781"><text><SENT sid="468" pm="."><plain>124.CooperS.T.McNeilP.L.Membrane Repair: Mechanisms and PathophysiologyPhysiol. </plain></SENT>
<SENT sid="469" pm="."><plain>Rev.2015951205124010.1152/physrev.00037.2014<?supplied-pmid 26336031?>26336031 </plain></SENT>
</text></ref><ref id="B125-ijms-19-01781"><text><SENT sid="470" pm="."><plain>125.KoerdtS.N.GerkeV.Annexin A2 is involved in Ca2+-dependent plasma membrane repair in primary human endothelial cellsBiochim. </plain></SENT>
<SENT sid="471" pm="."><plain>Biophys. </plain></SENT>
<SENT sid="472" pm="."><plain>Acta201718641046105310.1016/j.bbamcr.2016.12.007<?supplied-pmid 27956131?>27956131 </plain></SENT>
</text></ref><ref id="B126-ijms-19-01781"><text><SENT sid="473" pm="."><plain>126.DemonbreunA.R.QuattrocelliM.BarefieldD.Y.AllenM.V.SwansonK.E.McNallyE.M.An actin-dependent annexin complex mediates plasma membrane repair in muscleJ. </plain></SENT>
<SENT sid="474" pm="."><plain>Cell Biol.201621370571810.1083/jcb.201512022<?supplied-pmid 27298325?>27298325 </plain></SENT>
</text></ref><ref id="B127-ijms-19-01781"><text><SENT sid="475" pm="."><plain>127.SwaggartK.A.DemonbreunA.R.VoA.H.SwansonK.E.KimE.Y.FahrenbachJ.P.Holley-CuthrellJ.EskinA.ChenZ.SquireK.Annexin A6 modifies muscular dystrophy by mediating sarcolemmal repairProc. </plain></SENT>
<SENT sid="476" pm="."><plain>Natl. </plain></SENT>
<SENT sid="477" pm="."><plain>Acad. </plain></SENT>
<SENT sid="478" pm="."><plain>Sci. </plain></SENT>
<SENT sid="479" pm="."><plain>USA20141116004600910.1073/pnas.1324242111<?supplied-pmid 24717843?>24717843 </plain></SENT>
</text></ref><ref id="B128-ijms-19-01781"><text><SENT sid="480" pm="."><plain>128.BoyeT.L.NylandstedJ.Annexins in plasma membrane repairBiol. </plain></SENT>
<SENT sid="481" pm="."><plain>Chem.201639796196910.1515/hsz-2016-0171<?supplied-pmid 27341560?>27341560 </plain></SENT>
</text></ref><ref id="B129-ijms-19-01781"><text><SENT sid="482" pm="."><plain>129.LineroF.N.SepúlvedaC.S.GiovannoniF.CastillaV.GarcíaC.C.ScolaroL.A.DamonteE.B.Host cell factors as antiviral targets in arenavirus infectionViruses201241569159110.3390/v4091569<?supplied-pmid 23170173?>23170173 </plain></SENT>
</text></ref><ref id="B130-ijms-19-01781"><text><SENT sid="483" pm="."><plain>130.DaMattaR.A.SeabraS.H.DeolindoP.ArnholdtA.C.V.ManhãesL.GoldenbergS.de SouzaW.Trypanosoma cruzi exposes phosphatidylserine as an evasion mechanismFEMS Microbiol. </plain></SENT>
<SENT sid="484" pm="."><plain>Lett.2007266293310.1111/j.1574-6968.2006.00495.x<?supplied-pmid 17092297?>17092297 </plain></SENT>
</text></ref><ref id="B131-ijms-19-01781"><text><SENT sid="485" pm="."><plain>131.SeabraS.H.de SouzaW.DaMattaR.A.Toxoplasma gondii exposes phosphatidylserine inducing a TGF-β1 autocrine effect orchestrating macrophage evasionBiochem. </plain></SENT>
<SENT sid="486" pm="."><plain>Biophys. </plain></SENT>
<SENT sid="487" pm="."><plain>Res. </plain></SENT>
<SENT sid="488" pm="."><plain>Commun.200432474475210.1016/j.bbrc.2004.09.114<?supplied-pmid 15474490?>15474490 </plain></SENT>
</text></ref><ref id="B132-ijms-19-01781"><text><SENT sid="489" pm="."><plain>132.FariasL.H.S.RodriguesA.P.D.SilveiraF.T.SeabraS.H.DaMattaR.A.SaraivaE.M.SilvaE.O.Phosphatidylserine Exposure and Surface Sugars in Two Leishmania (Viannia) braziliensis Strains Involved in Cutaneous and Mucocutaneous LeishmaniasisJ. </plain></SENT>
<SENT sid="490" pm="."><plain>Infect. </plain></SENT>
<SENT sid="491" pm="."><plain>Dis.201320753754310.1093/infdis/jis689<?supplied-pmid 23148292?>23148292 </plain></SENT>
</text></ref><ref id="B133-ijms-19-01781"><text><SENT sid="492" pm="."><plain>133.ShawM.L.StoneK.L.ColangeloC.M.GulcicekE.E.PaleseP.Cellular Proteins in Influenza Virus ParticlesPLoS Pathog.20084e100008510.1371/journal.ppat.1000085<?supplied-pmid 18535660?>18535660 </plain></SENT>
</text></ref><ref id="B134-ijms-19-01781"><text><SENT sid="493" pm="."><plain>134.LoretS.GuayG.LippéR.Comprehensive characterization of extracellular herpes simplex virus type 1 virionsJ. </plain></SENT>
<SENT sid="494" pm="."><plain>Virol.2008828605861810.1128/JVI.00904-08<?supplied-pmid 18596102?>18596102 </plain></SENT>
</text></ref><ref id="B135-ijms-19-01781"><text><SENT sid="495" pm="."><plain>135.DryI.HaigD.M.InglisN.F.ImrieL.StewartJ.P.RussellG.C.Proteomic analysis of pathogenic and attenuated alcelaphine herpesvirus 1J. </plain></SENT>
<SENT sid="496" pm="."><plain>Virol.2008825390539710.1128/JVI.00094-08<?supplied-pmid 18353942?>18353942 </plain></SENT>
</text></ref><ref id="B136-ijms-19-01781"><text><SENT sid="497" pm="."><plain>136.VidickS.LeroyB.PalmeiraL.MachielsB.MastJ.FrançoisS.WattiezR.VanderplasschenA.GilletL.Proteomic Characterization of Murid Herpesvirus 4 Extracellular VirionsPLoS ONE20138e8384210.1371/journal.pone.0083842<?supplied-pmid 24386290?>24386290 </plain></SENT>
</text></ref><ref id="B137-ijms-19-01781"><text><SENT sid="498" pm="."><plain>137.KattenhornL.M.MillsR.WagnerM.LomsadzeA.MakeevV.BorodovskyM.PloeghH.L.KesslerB.M.Identification of Proteins Associated with Murine Cytomegalovirus VirionsJ. </plain></SENT>
<SENT sid="499" pm="."><plain>Virol.200478111871119710.1128/JVI.78.20.11187-11197.2004<?supplied-pmid 15452238?>15452238 </plain></SENT>
</text></ref><ref id="B138-ijms-19-01781"><text><SENT sid="500" pm="."><plain>138.ChertovaE.ChertovO.CorenL.V.RoserJ.D.TrubeyC.M.BessJ.W.SowderR.C.BarsovE.HoodB.L.FisherR.J.Proteomic and Biochemical Analysis of Purified Human Immunodeficiency Virus Type 1 Produced from Infected Monocyte-Derived MacrophagesJ. </plain></SENT>
<SENT sid="501" pm="."><plain>Virol.2006809039905210.1128/JVI.01013-06<?supplied-pmid 16940516?>16940516 </plain></SENT>
</text></ref><ref id="B139-ijms-19-01781"><text><SENT sid="502" pm="."><plain>139.Moerdyk-SchauweckerM.HwangS.GrdzelishviliV.Z.Analysis of virion associated host proteins in vesicular stomatitis virus using a proteomics approachVirol. </plain></SENT>
<SENT sid="503" pm="."><plain>J.2009616610.1186/1743-422X-6-166<?supplied-pmid 19821998?>19821998 </plain></SENT>
</text></ref><ref id="B140-ijms-19-01781"><text><SENT sid="504" pm="."><plain>140.Moerdyk-SchauweckerM.HwangS.GrdzelishviliV.Z.Cellular Proteins Associated with the Interior and Exterior of Vesicular Stomatitis Virus VirionsPLoS ONE20149e10468810.1371/journal.pone.0104688<?supplied-pmid 25105980?>25105980 </plain></SENT>
</text></ref><ref id="B141-ijms-19-01781"><text><SENT sid="505" pm="."><plain>141.NussJ.E.Kehn-HallK.BenedictA.CostantinoJ.WardM.PeyserB.D.RettererC.J.TresslerL.E.WannerL.M.McGovernH.F.Multi-faceted proteomic characterization of host protein complement of Rift Valley fever virus virions and identification of specific heat shock proteins, including HSP90, as important viral host factorsPLoS ONE20149e9348310.1371/journal.pone.0093483<?supplied-pmid 24809507?>24809507 </plain></SENT>
</text></ref><ref id="B142-ijms-19-01781"><text><SENT sid="506" pm="."><plain>142.TcherniukS.CenacN.ComteM.FrouardJ.Errazuriz-CerdaE.GalabovA.MorangeP.VergnolleN.Si-TaharM.AlessiM.Formyl Peptide Receptor 2 Plays a Deleterious Role During Influenza A Virus InfectionsJ. </plain></SENT>
<SENT sid="507" pm="."><plain>Infect. </plain></SENT>
<SENT sid="508" pm="."><plain>Dis.201621423724710.1093/infdis/jiw127<?supplied-pmid 27034344?>27034344 </plain></SENT>
</text></ref><ref id="B143-ijms-19-01781"><text><SENT sid="509" pm="."><plain>143.AlessiM.CenacN.Si-TaharM.RiteauB.FPR2: A Novel Promising Target for the Treatment of InfluenzaFront. </plain></SENT>
<SENT sid="510" pm="."><plain>Microbiol.20178171910.3389/fmicb.2017.01719<?supplied-pmid 28928730?>28928730 </plain></SENT>
</text></ref><ref id="B144-ijms-19-01781"><text><SENT sid="511" pm="."><plain>144.GershomE.S.HoekA.L.V.MeixnerS.C.SutherlandM.R.PryzdialE.L.G.Herpesviruses enhance fibrin clot lysisThromb. </plain></SENT>
<SENT sid="512" pm="."><plain>Haemost.201210776076810.1160/TH11-08-0601<?supplied-pmid 22318336?>22318336 </plain></SENT>
</text></ref><ref id="B145-ijms-19-01781"><text><SENT sid="513" pm="."><plain>145.LeBouderF.LinaB.RimmelzwaanG.F.RiteauB.Plasminogen promotes influenza A virus replication through an annexin 2-dependent pathway in the absence of neuraminidaseJ. </plain></SENT>
<SENT sid="514" pm="."><plain>Gen. </plain></SENT>
<SENT sid="515" pm="."><plain>Virol.2010912753276110.1099/vir.0.023804-0<?supplied-pmid 20702651?>20702651 </plain></SENT>
</text></ref><ref id="B146-ijms-19-01781"><text><SENT sid="516" pm="."><plain>146.LeBouderF.MorelloE.RimmelzwaanG.F.BosseF.PéchouxC.DelmasB.RiteauB.Annexin II incorporated into influenza virus particles supports virus replication by converting plasminogen into plasminJ. </plain></SENT>
<SENT sid="517" pm="."><plain>Virol.2008826820682810.1128/JVI.00246-08<?supplied-pmid 18448517?>18448517 </plain></SENT>
</text></ref><ref id="B147-ijms-19-01781"><text><SENT sid="518" pm="."><plain>147.LiuC.ZhangA.GuoJ.YangJ.ZhouH.ChenH.JinM.Identification of human host proteins contributing to H5N1 influenza virus propagation by membrane proteomicsJ. </plain></SENT>
<SENT sid="519" pm="."><plain>Proteome Res.2012115396540510.1021/pr3006342<?supplied-pmid 22985253?>22985253 </plain></SENT>
</text></ref><ref id="B148-ijms-19-01781"><text><SENT sid="520" pm="."><plain>148.BerriF.HaffarG.LeV.B.SadewasserA.PakiK.LinaB.WolffT.RiteauB.Annexin V Incorporated into Influenza Virus Particles Inhibits Gamma Interferon Signaling and Promotes Viral ReplicationJ. </plain></SENT>
<SENT sid="521" pm="."><plain>Virol.201488112151122810.1128/JVI.01405-14<?supplied-pmid 25031344?>25031344 </plain></SENT>
</text></ref><ref id="B149-ijms-19-01781"><text><SENT sid="522" pm="."><plain>149.HertogsK.LeendersW.P.DeplaE.de BruinW.C.MeheusL.RaymackersJ.MoshageH.YapS.H.Endonexin II, present on human liver plasma membranes, is a specific binding protein of small hepatitis B virus (HBV) envelope proteinVirology199319754955710.1006/viro.1993.1628<?supplied-pmid 8249278?>8249278 </plain></SENT>
</text></ref><ref id="B150-ijms-19-01781"><text><SENT sid="523" pm="."><plain>150.NeurathA.R.StrickN.The putative cell receptors for hepatitis B virus (HBV), annexin V, and apolipoprotein H, bind to lipid components of HBVVirology199420447547710.1006/viro.1994.1558<?supplied-pmid 8091682?>8091682 </plain></SENT>
</text></ref><ref id="B151-ijms-19-01781"><text><SENT sid="524" pm="."><plain>151.De MeyerS.GongZ.DeplaE.MaertensG.YapS.H.Involvement of phosphatidylserine and non-phospholipid components of the hepatitis B virus envelope in human Annexin V binding and in HBV infection in vitroJ. </plain></SENT>
<SENT sid="525" pm="."><plain>Hepatol.19993178379010.1016/S0168-8278(99)80278-510580574 </plain></SENT>
</text></ref><ref id="B152-ijms-19-01781"><text><SENT sid="526" pm="."><plain>152.De MeyerS.GongZ.J.HertogsK.DeplaE.van PeltJ.F.RoskamsT.MaertensG.YapS.H.Influence of the administration of human annexin V on in vitro binding of small hepatitis B surface antigen to human and to rat hepatocytes and on in vitro hepatitis B virus infectionJ. </plain></SENT>
<SENT sid="527" pm="."><plain>Viral Hepat.2000710411410.1046/j.1365-2893.2000.00207.x<?supplied-pmid 10760040?>10760040 </plain></SENT>
</text></ref><ref id="B153-ijms-19-01781"><text><SENT sid="528" pm="."><plain>153.GongZ.J.de MeyerS.van PeltJ.HertogsK.DeplaE.SoumillionA.FeveryJ.YapS.H.Transfection of a rat hepatoma cell line with a construct expressing human liver annexin V confers susceptibility to hepatitis B virus infectionHepatology19992957658410.1002/hep.510290238<?supplied-pmid 9918938?>9918938 </plain></SENT>
</text></ref><ref id="B154-ijms-19-01781"><text><SENT sid="529" pm="."><plain>154.De MeyerS.DeplaE.MaertensG.SoumillionA.YapS.H.Characterization of small hepatitis B surface antigen epitopes involved in binding to human annexin VJ. </plain></SENT>
<SENT sid="530" pm="."><plain>Viral Hepat.1999627728510.1046/j.1365-2893.1999.00167.x<?supplied-pmid 10607242?>10607242 </plain></SENT>
</text></ref><ref id="B155-ijms-19-01781"><text><SENT sid="531" pm="."><plain>155.WoodhamA.W.da SilvaD.M.SkeateJ.G.RaffA.B.AmbrosoM.R.BrandH.E.IsasJ.M.LangenR.KastW.M.The S100A10 subunit of the annexin A2 heterotetramer facilitates L2-mediated human papillomavirus infectionPLoS ONE20127e4351910.1371/journal.pone.0043519<?supplied-pmid 22927980?>22927980 </plain></SENT>
</text></ref><ref id="B156-ijms-19-01781"><text><SENT sid="532" pm="."><plain>156.DziduszkoA.OzbunM.A.Annexin A2 and S100A10 regulate human papillomavirus type 16 entry and intracellular trafficking in human keratinocytesJ. </plain></SENT>
<SENT sid="533" pm="."><plain>Virol.2013877502751510.1128/JVI.00519-1323637395 </plain></SENT>
</text></ref><ref id="B157-ijms-19-01781"><text><SENT sid="534" pm="."><plain>157.WoodhamA.W.TaylorJ.R.JimenezA.I.SkeateJ.G.SchmidtT.BrandH.E.da SilvaD.M.KastW.M.Small molecule inhibitors of the annexin A2 heterotetramer prevent human papillomavirus type 16 infectionJ. </plain></SENT>
<SENT sid="535" pm="."><plain>Antimicrob. </plain></SENT>
<SENT sid="536" pm="."><plain>Chemother.2015701686169010.1093/jac/dkv045<?supplied-pmid 25712315?>25712315 </plain></SENT>
</text></ref><ref id="B158-ijms-19-01781"><text><SENT sid="537" pm="."><plain>158.PietropaoloR.L.ComptonT.Direct interaction between human cytomegalovirus glycoprotein B and cellular annexin IIJ. </plain></SENT>
<SENT sid="538" pm="."><plain>Virol.19977198039807<?supplied-pmid 9371650?>9371650 </plain></SENT>
</text></ref><ref id="B159-ijms-19-01781"><text><SENT sid="539" pm="."><plain>159.BoldS.OhlinM.GartenW.RadsakK.Structural domains involved in human cytomegalovirus glycoprotein B-mediated cell-cell fusionJ. </plain></SENT>
<SENT sid="540" pm="."><plain>Gen. </plain></SENT>
<SENT sid="541" pm="."><plain>Virol.1996772297230210.1099/0022-1317-77-9-2297<?supplied-pmid 8811030?>8811030 </plain></SENT>
</text></ref><ref id="B160-ijms-19-01781"><text><SENT sid="542" pm="."><plain>160.DerryM.C.SutherlandM.R.RestallC.M.WaismanD.M.PryzdialE.L.G.Annexin 2-mediated enhancement of cytomegalovirus infection opposes inhibition by annexin 1 or annexin 5J. </plain></SENT>
<SENT sid="543" pm="."><plain>Gen. </plain></SENT>
<SENT sid="544" pm="."><plain>Virol.200788192710.1099/vir.0.82294-0<?supplied-pmid 17170432?>17170432 </plain></SENT>
</text></ref><ref id="B161-ijms-19-01781"><text><SENT sid="545" pm="."><plain>161.González-ReyesS.García-MansoA.del BarrioG.DaltonK.P.González-MolledaL.Arrojo-FernándezJ.NiciezaI.ParraF.Role of annexin A2 in cellular entry of rabbit vesivirusJ. </plain></SENT>
<SENT sid="546" pm="."><plain>Gen. </plain></SENT>
<SENT sid="547" pm="."><plain>Virol.2009902724273010.1099/vir.0.013276-0<?supplied-pmid 19605586?>19605586 </plain></SENT>
</text></ref><ref id="B162-ijms-19-01781"><text><SENT sid="548" pm="."><plain>162.MalhotraR.WardM.BrightH.PriestR.FosterM.R.HurleM.BlairE.BirdM.Isolation and characterisation of potential respiratory syncytial virus receptor(s) on epithelial cellsMicrobes Infect.2003512313310.1016/S1286-4579(02)00079-512650770 </plain></SENT>
</text></ref><ref id="B163-ijms-19-01781"><text><SENT sid="549" pm="."><plain>163.YangS.ChouY.WuC.HoM.Annexin II binds to capsid protein VP1 of enterovirus 71 and enhances viral infectivityJ. </plain></SENT>
<SENT sid="550" pm="."><plain>Virol.201185118091182010.1128/JVI.00297-11<?supplied-pmid 21900167?>21900167 </plain></SENT>
</text></ref><ref id="B164-ijms-19-01781"><text><SENT sid="551" pm="."><plain>164.KirschnekS.AdamsC.GulbinsE.Annexin II is a novel receptor for Pseudomonas aeruginosaBiochem. </plain></SENT>
<SENT sid="552" pm="."><plain>Biophys. </plain></SENT>
<SENT sid="553" pm="."><plain>Res. </plain></SENT>
<SENT sid="554" pm="."><plain>Commun.200532790090610.1016/j.bbrc.2004.12.089<?supplied-pmid 15649430?>15649430 </plain></SENT>
</text></ref><ref id="B165-ijms-19-01781"><text><SENT sid="555" pm="."><plain>165.YuanS.QuL.ShouC.N-Terminal Polypeptide of Annexin A2 Decreases Infection of Mycoplasma hyorhinis to Gastric Cancer CellsPLoS ONE201611e014777610.1371/journal.pone.0147776<?supplied-pmid 26812398?>26812398 </plain></SENT>
</text></ref><ref id="B166-ijms-19-01781"><text><SENT sid="556" pm="."><plain>166.SomarajanS.R.Al-AsadiF.RamasamyK.PandrankiL.BasemanJ.B.KannanT.R.Annexin A2 mediates Mycoplasma pneumoniae community-acquired respiratory distress syndrome toxin binding to eukaryotic cellsMBio2014510.1128/mBio.01497-14<?supplied-pmid 25139904?>25139904 </plain></SENT>
</text></ref><ref id="B167-ijms-19-01781"><text><SENT sid="557" pm="."><plain>167.HamH.SreelathaA.OrthK.Manipulation of host membranes by bacterial effectorsNat. </plain></SENT>
<SENT sid="558" pm="."><plain>Rev. </plain></SENT>
<SENT sid="559" pm="."><plain>Microbiol.2011963564610.1038/nrmicro2602<?supplied-pmid 21765451?>21765451 </plain></SENT>
</text></ref><ref id="B168-ijms-19-01781"><text><SENT sid="560" pm="."><plain>168.PotezS.LuginbühlM.MonastyrskayaK.HostettlerA.DraegerA.BabiychukE.B.Tailored protection against plasmalemmal injury by annexins with different Ca2+ sensitivitiesJ. </plain></SENT>
<SENT sid="561" pm="."><plain>Biol. </plain></SENT>
<SENT sid="562" pm="."><plain>Chem.2011286179821799110.1074/jbc.M110.187625<?supplied-pmid 21454475?>21454475 </plain></SENT>
</text></ref><ref id="B169-ijms-19-01781"><text><SENT sid="563" pm="."><plain>169.BabiychukE.B.MonastyrskayaK.PotezS.DraegerA.Blebbing confers resistance against cell lysisCell Death Differ.201118808910.1038/cdd.2010.81<?supplied-pmid 20596076?>20596076 </plain></SENT>
</text></ref><ref id="B170-ijms-19-01781"><text><SENT sid="564" pm="."><plain>170.HenryB.D.NeillD.R.BeckerK.A.GoreS.Bricio-MorenoL.ZiobroR.EdwardsM.J.MühlemannK.SteinmannJ.KleuserB.Engineered liposomes sequester bacterial exotoxins and protect from severe invasive infections in miceNat. </plain></SENT>
<SENT sid="565" pm="."><plain>Biotechnol.201533818810.1038/nbt.3037<?supplied-pmid 25362245?>25362245 </plain></SENT>
</text></ref><ref id="B171-ijms-19-01781"><text><SENT sid="566" pm="."><plain>171.LuisoniS.SuomalainenM.BouckeK.TannerL.B.WenkM.R.GuanX.L.GrzybekM.CoskunÜ.GreberU.F.Co-option of Membrane Wounding Enables Virus Penetration into CellsCell Host Microbe201518758510.1016/j.chom.2015.06.006<?supplied-pmid 26159720?>26159720 </plain></SENT>
</text></ref><ref id="B172-ijms-19-01781"><text><SENT sid="567" pm="."><plain>172.RoyD.ListonD.R.IdoneV.J.DiA.NelsonD.J.PujolC.BliskaJ.B.ChakrabartiS.AndrewsN.W.A Process for Controlling Intracellular Bacterial Infections Induced by Membrane InjuryScience20043041515151810.1126/science.1098371<?supplied-pmid 15178804?>15178804 </plain></SENT>
</text></ref><ref id="B173-ijms-19-01781"><text><SENT sid="568" pm="."><plain>173.PoeterM.BrandhermI.RossaintJ.RossoG.ShahinV.SkryabinB.V.ZarbockA.GerkeV.RescherU.Annexin A8 controls leukocyte recruitment to activated endothelial cells via cell surface delivery of CD63Nat. </plain></SENT>
<SENT sid="569" pm="."><plain>Commun.20145373810.1038/ncomms4738<?supplied-pmid 24769558?>24769558 </plain></SENT>
</text></ref><ref id="B174-ijms-19-01781"><text><SENT sid="570" pm="."><plain>174.BrandhermI.DisseJ.ZeuschnerD.GerkeV.cAMP-induced secretion of endothelial von Willebrand factor is regulated by a phosphorylation/dephosphorylation switch in annexin A2Blood20131221042105110.1182/blood-2012-12-475251<?supplied-pmid 23757730?>23757730 </plain></SENT>
</text></ref><ref id="B175-ijms-19-01781"><text><SENT sid="571" pm="."><plain>175.MusiolA.GranS.EhrhardtC.LudwigS.GrewalT.GerkeV.RescherU.Annexin A6-balanced late endosomal cholesterol controls influenza A replication and propagationMBio20134e00608-1310.1128/mBio.00608-13<?supplied-pmid 24194536?>24194536 </plain></SENT>
</text></ref><ref id="B176-ijms-19-01781"><text><SENT sid="572" pm="."><plain>176.BackesP.QuinkertD.ReissS.BinderM.ZayasM.RescherU.GerkeV.BartenschlagerR.LohmannV.Role of annexin A2 in the production of infectious hepatitis C virus particlesJ. </plain></SENT>
<SENT sid="573" pm="."><plain>Virol.2010845775578910.1128/JVI.02343-09<?supplied-pmid 20335258?>20335258 </plain></SENT>
</text></ref><ref id="B177-ijms-19-01781"><text><SENT sid="574" pm="."><plain>177.SaxenaV.LaiC.ChaoT.JengK.LaiM.M.C.Annexin A2 Is Involved in the Formation of Hepatitis C Virus Replication Complex on the Lipid RaftJ. </plain></SENT>
<SENT sid="575" pm="."><plain>Virol.2012864139415010.1128/JVI.06327-11<?supplied-pmid 22301157?>22301157 </plain></SENT>
</text></ref><ref id="B178-ijms-19-01781"><text><SENT sid="576" pm="."><plain>178.LaiC.JengK.MachidaK.LaiM.M.C.Association of hepatitis C virus replication complexes with microtubules and actin filaments is dependent on the interaction of NS3 and NS5AJ. </plain></SENT>
<SENT sid="577" pm="."><plain>Virol.2008828838884810.1128/JVI.00398-08<?supplied-pmid 18562541?>18562541 </plain></SENT>
</text></ref><ref id="B179-ijms-19-01781"><text><SENT sid="578" pm="."><plain>179.RöschK.KwiatkowskiM.HofmannS.SchöbelA.GrüttnerC.WurlitzerM.SchlüterH.HerkerE.Quantitative Lipid Droplet Proteome Analysis Identifies Annexin A3 as a Cofactor for HCV Particle ProductionCell Rep.2016163219323110.1016/j.celrep.2016.08.052<?supplied-pmid 27653686?>27653686 </plain></SENT>
</text></ref></ref-list></SecTag></back><floats-group><SecTag type="FIG"><fig id="ijms-19-01781-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p><text><SENT sid="579" pm="."><plain>Overview of diseases associated with changes in annexin expression levels. </plain></SENT>
<SENT sid="580" pm="."><plain>Abbreviation: T2D: Type 2 diabetes mellitus [93]; APS: antiphospholipid syndrome [43]; APL: promyelocytic leukemia [50]; HCV: hepatitis C virus [94]; IAV: influenza A virus [95]; KSHV: Kaposi’s sarcoma-associated herpesvirus [96]; EBV: Epstein-Barr-Virus [97]; HPV: Human papillomavirus [98]; M. tuberculosis: Mycobacterium tuberculosis [99]. </plain></SENT>
</text></p></caption><graphic xlink:href="ijms-19-01781-g001"/></fig></SecTag></floats-group></article>
